US20160008557A1 - Dry powder inhalation system - Google Patents
Dry powder inhalation system Download PDFInfo
- Publication number
- US20160008557A1 US20160008557A1 US14/863,136 US201514863136A US2016008557A1 US 20160008557 A1 US20160008557 A1 US 20160008557A1 US 201514863136 A US201514863136 A US 201514863136A US 2016008557 A1 US2016008557 A1 US 2016008557A1
- Authority
- US
- United States
- Prior art keywords
- mouthpiece
- cartridge
- dry powder
- housing
- inhalation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000843 powder Substances 0.000 title claims description 51
- 229940112141 dry powder inhaler Drugs 0.000 claims abstract description 66
- 239000003814 drug Substances 0.000 claims abstract description 45
- 230000002685 pulmonary effect Effects 0.000 claims abstract description 11
- 239000003570 air Substances 0.000 claims description 58
- 230000007246 mechanism Effects 0.000 claims description 22
- 239000004480 active ingredient Substances 0.000 claims description 11
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 claims description 10
- 238000004891 communication Methods 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 239000012080 ambient air Substances 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 61
- 102000004877 Insulin Human genes 0.000 description 30
- 229940125396 insulin Drugs 0.000 description 30
- 108090001061 Insulin Proteins 0.000 description 28
- 239000000203 mixture Substances 0.000 description 22
- 238000009472 formulation Methods 0.000 description 19
- 229940079593 drug Drugs 0.000 description 13
- 238000000034 method Methods 0.000 description 9
- 230000003434 inspiratory effect Effects 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 108010065920 Insulin Lispro Proteins 0.000 description 7
- 230000013011 mating Effects 0.000 description 7
- 239000013543 active substance Substances 0.000 description 6
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 6
- 238000012377 drug delivery Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 4
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 4
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 4
- 102000043299 Parathyroid hormone-related Human genes 0.000 description 4
- 101710123753 Parathyroid hormone-related protein Proteins 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 229940038661 humalog Drugs 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000003982 Parathyroid hormone Human genes 0.000 description 3
- 108090000445 Parathyroid hormone Proteins 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000000199 parathyroid hormone Substances 0.000 description 3
- 229960001319 parathyroid hormone Drugs 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000004088 pulmonary circulation Effects 0.000 description 3
- BBNKIRVUCQNAQR-FETIZUMASA-N (e)-4-[4-[(2s,5s)-5-[4-[[(e)-3-carboxyprop-2-enoyl]amino]butyl]-3,6-dioxopiperazin-2-yl]butylamino]-4-oxobut-2-enoic acid Chemical compound OC(=O)\C=C\C(=O)NCCCC[C@@H]1NC(=O)[C@H](CCCCNC(=O)\C=C\C(O)=O)NC1=O BBNKIRVUCQNAQR-FETIZUMASA-N 0.000 description 2
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 description 2
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 2
- 101710092928 Insulin-like peptide-1 Proteins 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 229940094417 fumaryl diketopiperazine Drugs 0.000 description 2
- -1 glutaryl Chemical group 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229960002068 insulin lispro Drugs 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- QIQCZROILFZKAT-UHFFFAOYSA-N tetracarbon dioxide Chemical group O=C=C=C=C=O QIQCZROILFZKAT-UHFFFAOYSA-N 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 125000000349 (Z)-3-carboxyprop-2-enoyl group Chemical group O=C([*])/C([H])=C([H])\C(O[H])=O 0.000 description 1
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- COGGPXCGDJASNA-UHFFFAOYSA-N O=C(O)CCC(=O)CCCCCC1NC(=O)C(CCCCNC(=O)CCC(=O)O)NC1=O Chemical compound O=C(O)CCC(=O)CCCCCC1NC(=O)C(CCCCNC(=O)CCC(=O)O)NC1=O COGGPXCGDJASNA-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102400000319 Oxyntomodulin Human genes 0.000 description 1
- 101800001388 Oxyntomodulin Proteins 0.000 description 1
- 102100029909 Peptide YY Human genes 0.000 description 1
- 108010088847 Peptide YY Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229940123452 Rapid-acting insulin Drugs 0.000 description 1
- 108010026951 Short-Acting Insulin Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000012383 pulmonary drug delivery Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
- A61M15/0023—Mouthpieces therefor retractable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
- A61M15/0015—Details of inhalators; Constructional features thereof with inhalation check valves located upstream of the dispenser, i.e. not traversed by the product
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/002—Details of inhalators; Constructional features thereof with air flow regulating means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0043—Non-destructive separation of the package, e.g. peeling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/0015—Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors
- A61M2016/0018—Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors electrical
- A61M2016/0021—Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors electrical with a proportional output signal, e.g. from a thermistor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/0027—Accessories therefor, e.g. sensors, vibrators, negative pressure pressure meter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/07—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/581—Means for facilitating use, e.g. by people with impaired vision by audible feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/582—Means for facilitating use, e.g. by people with impaired vision by tactile feedback
Definitions
- a pulmonary drug delivery system includes a dry powder inhaler; and a unit dose cartridge for using with the inhaler.
- the cartridge can contain a drug delivery formulation for pulmonary delivery, for example, a formulation comprising a diketopiperazine and an active ingredient including peptides and proteins such as insulin and glucagon-like peptide 1.
- the dry powder inhaler is compact and comprises a housing, and a mouthpiece having a chamber to install the unit dose cartridge containing medicament and can be separated from its housing for ease of cleaning.
- Drug delivery systems for the treatment of disease which introduce active ingredients into the circulation are numerous and include oral, transdermal, inhalation, subcutaneous and intravenous administration.
- Drugs delivered by inhalation are typically delivered using positive pressure relative to atmospheric pressure in air with propellants.
- Such drug delivery systems deliver drugs as aerosols, nebulized or vaporized.
- drug delivery to lung tissue has been achieved with dry powder inhalers. Dry powder inhalers can be breath-activated to deliver drugs by converting drug particles in a carrier into a fine dry powder which is entrained into an airflow and inhaled by the patient.
- Drugs delivered with the use of a dry powder inhaler can no longer be intended to treat pulmonary disease only, but also specific drugs can be used to treat many conditions, including diabetes and obesity.
- Dry powder inhalers used to deliver medicaments to the lungs, contain a dose system of a powder formulation usually either in bulk supply or quantified into individual doses stored in unit dose compartments, like hard gelatin capsules or blister packs.
- Bulk containers are equipped with a measuring system operated by the patient in order to isolate a single dose from the powder immediately before inhalation. Dosing reproducibility requires that the drug formulation is uniform and that the dose can be delivered to the patient with consistent and reproducible results. Therefore, the dosing system must operate to completely discharge all of the formulation effectively during an inspiratory maneuver when the patient is taking his/her dose.
- Flow properties of the powder formulation, and long term physical and mechanical stability in this respect are more critical for bulk containers than they are for single unit dose compartments. Good moisture protection can be achieved more easily for unit dose compartments such as blisters, however, foils used to seal the blisters and subsequent drug formulation lose viability with long storage.
- Dry powder inhalers such as those describe in U.S. Pat. No. 7,305,986 and U.S. patent application Ser. No. 10/655,153 (US 20040182387), the disclosures of which are incorporated herein by reference in their entirety for all they disclose regarding dry powder inhalers, can generate primary drug particles or suitable inhalation plumes during an inspiratory maneuver by deagglomerating the powder formulation within a capsule.
- the amount of fine drug discharged from the inhaler's mouthpiece during inhalation is largely dependent on the interparticulate forces in the powder formulation (between drug and drug particles or between drug and excipient particles) and the efficiency of the airflow as measured by pressure drop and flow rate entering and exiting the dry powder dispenser.
- the benefits of delivering drugs via the pulmonary circulation are numerous and include, rapid absorption into the arterial circulation, avoidance of drug degradation by liver metabolism, ease of use, i.e., lack of discomfort of administration by other routes of administration.
- Dry powder inhaler products developed for pulmonary inhalation have met with limited success to date, due to lack of practicality.
- Dry powder inhaler systems for pulmonary delivery of pharmaceuticals are disclosed.
- the dry powder inhalation systems comprise a dry powder inhalation device or inhaler and at least one cartridge containing a pharmaceutical formulation comprising at least one active ingredient for delivery to the pulmonary circulation.
- the present inhalation systems provide rugged devices which are reusable, use pre-metered unit dose cartridges and can be separated into their principal component parts for ease of cleaning.
- the devices also provide high resistance inhalation systems which enable deagglomeration of dry powder particles, have consistent airflow and are simple and easy to use.
- a dry powder inhaler comprises a housing, and a mouthpiece, wherein the housing comprises a mouthpiece engaging section structurally configured to engage with the mouthpiece, and the mouthpiece being removable at predetermined positions relative to the housing, and having a conduit permitting airflow between an air inlet and an air exit port, and comprising a chamber and an oral placement section; the mouthpiece further being structurally configured to be moveable within the housing in an engaged position and releasable from the housing at a predetermined position.
- the dry powder inhaler mouthpiece is structurally configured to receive, hold and/or release a medicament containing cartridge in the chamber.
- the housing comprises a container structurally configured to adapt to the mouthpiece and has one or more openings for allowing air intake into the mouthpiece chamber.
- the housing has securing mechanisms to hold the mouthpiece chamber and permit the mouthpiece assembly to be moveable within the housing to a storage position, to a cartridge loading/unloading position, mouthpiece separable position, to an inhalation position and in reversed order.
- the mouthpiece assembly engages the mouthpiece at the mouthpiece engaging section of the housing.
- the housing can comprise an air intake section having an air conduit with one or more first openings to allow ambient air intake and a second opening in communication with the mouthpiece engaging section which allows airflow through the air conduit and out into the housing engaging section, the engagement of the mouthpiece substantially prevents ambient air from entering the conduit except at the one or more first openings in the housing for air intake.
- the housing also comprises a mouthpiece storage section.
- the dry powder inhaler mouthpiece assembly can move relative to the housing and the movement of the mouthpiece within the housing can reconfigure a cartridge seated in the inhaler from a closed configuration to an open configuration, or from an open to a closed configuration.
- Movement of the mouthpiece within the housing can be of various types, such as translational or rotational.
- movement about the housing is rotational, and can be restricted at predetermined locations relative to the housing to provide registration of positions of the mouthpiece in use.
- movement of the mouthpiece assembly is rotational and the mouthpiece can rotate from the storage position to a cartridge loading/unloading position to an inhalation position.
- the mouthpiece further comprises a mouthpiece oral placement section and a medicament containing cartridge receiving section; the cartridge receiving section configured to permit and direct air flow through and around the cartridge.
- the air conduit of the air intake section of the housing is in communication with the air exit port of the mouthpiece when the cartridge is in an open configuration.
- the airflow conduit is established between one or more first openings in the housing; then air passes through the airflow conduit within the housing and exits a second opening of the mouthpiece engaging section and enters into the mouthpiece chamber wherein a percentage of intake air volume goes through the cartridge and a percentage of intake air volume goes around the cartridge during an inhalation maneuver.
- the airflow path then enters the mouthpiece chamber and enters and exits the conduit of the mouthpiece oral placement section.
- airflow entering the chamber from the housing outlet port is diverted so that a percentage of the airflow volume goes through the cartridge and a percentage of the airflow volume goes around the cartridge.
- a dry powder inhaler comprising a housing, and a mouthpiece assembly, the housing having a top wall, a bottom wall, side walls; a mouthpiece engaging section, a mouthpiece storage section, and an air intake section having a conduit with a first opening to allow ambient air intake and a second opening in communication with the mouthpiece engaging section which allows air flow therethrough; the mouthpiece subassembly being removable and comprising a chamber structurally configured to house a cartridge and to engage with the mouthpiece engaging section of the housing; an oral placement section extending from the chamber and having an air inlet which communicates with the chamber and an air outlet in communication with ambient air.
- a breath-powered inhaler comprising, an inhaler with resistance values that can be tunable or changed as required by the patient being an adult or a child.
- the resistance values of the inhaler can be altered by changing the geometries or configuration of the air conduits so that airflow distribution through the cartridge and around the cartridge can vary.
- inhaler resistance values can range between 0.08 and 0.15 ⁇ kPa/liters per minute.
- flow balance distribution can range from about 10% to about 30% through the cartridge and from about 70% to 90% going around the cartridge.
- the dry powder inhalation system comprises a breath-activated dry powder inhaler, a cartridge containing medicament, wherein the medicament can comprise a diketopiperazine and an active agent.
- the active agent comprises peptides and proteins.
- the inhalation system comprises a cartridge containing medicament wherein the peptide or protein can be an endocrine hormone: including, insulin, glucose-like peptide (GLP-1), parathyroid hormone, parathyroid hormone related protein (PTHrP), and the like.
- the dry powder inhalation system can comprise a cartridge including a formulation for pulmonary delivery which can be provided for use with different dosage strengths, wherein the system can deliver the dosage with consistency and in a linear manner.
- a cartridge including a formulation for pulmonary delivery which can be provided for use with different dosage strengths, wherein the system can deliver the dosage with consistency and in a linear manner.
- multiple cartridges of a single dose to be administered to a subject can be interchangeably replaced or substituted by providing the system with a single cartridge of the sum of the dosage strength of the multiple cartridges, wherein the system can deliver a bioequivalent dose with a single cartridge.
- FIG. 1 illustrates a three dimensional side view of an embodiment of a dry powder inhaler in a storage position.
- FIG. 2 illustrates the back side view of the dry powder inhaler of FIG. 1 showing the mouthpiece subassembly moved from the storage position to a cartridge loading position wherein the cap is opened. In this embodiment, this is also the position at which the mouthpiece can be separated.
- FIG. 3 illustrates the back side view of the dry powder inhaler of FIG. 1 showing the mouthpiece subassembly has been moved to the inhalation position for use.
- FIG. 4 illustrates the back side view of the dry powder inhaler of FIG. 1 showing the mouthpiece subassembly has been moved to an unloading position after inhalation.
- FIG. 5 illustrates the dry powder inhaler of FIG. 1 , showing the housing subassembly and the mouthpiece subassembly disengaged from one another.
- FIG. 6 illustrates a top view section of a housing subassembly of a dry powder inhaler.
- FIG. 7 illustrates the dry powder inhaler shown in FIG. 3 in cross-section.
- FIG. 8 illustrates the dry powder inhaler of FIG. 1 , showing an exploded view of the housing subassembly.
- FIG. 9 illustrates the dry powder inhaler of FIG. 1 , showing the mouthpiece subassembly removed from the housing component.
- FIG. 10 illustrates the dry powder inhaler of FIG. 1 , showing an exploded view of the mouthpiece subassembly.
- FIG. 11 illustrates an alternate embodiment of the dry powder inhaler system showing the inhaler in a cartridge loading position.
- FIG. 11 also depicts a cartridge embodiment for use with a dry powder inhaler according to the present description.
- FIG. 12 illustrates the embodiment of FIG. 11 with a cartridge loaded into the dry powder inhaler with the cap open.
- FIG. 13 illustrates the embodiment of FIG. 11 showing the dry powder inhaler in an inhalation position.
- FIG. 14 illustrates the embodiment of FIG. 13 showing the dry powder inhaler in inhalation position as a cross-section through the mid-longitudinal axis.
- FIG. 15 illustrates a cross-section of an embodiment wherein the dry powder inhaler is shown in the dosing position and containing a cartridge.
- FIG. 16 illustrates an embodiment of a three dimensional side view of a cartridge for use with the dry powder inhalation system.
- FIG. 17 illustrates an embodiment of a three dimensional back side view cartridge for use with the dry powder inhalation system.
- FIG. 18 illustrates an embodiment of an exploded three dimensional view of the cartridge for use with the dry powder inhalation system.
- FIG. 19 illustrates a mean baseline-corrected GIR (glucose infusion rate) for two 15 U cartridges and one 30 U cartridge of an inhalation powder comprising insulin and fumaryl diketopiperazine, and for 10 IU of RAA.
- FIG. 20A depicts a schematic representation of a cartridge loaded into a cartridge rig in cross-section for measuring pressure across the cartridge.
- FIG. 20B illustrates a diagram of a resistance circuit illustrating the various resistors associated with the cartridge rig illustrated in FIG. 20A .
- FIG. 21A illustrates a schematic representation of a portion of the inhaler in cross-section showing components parts.
- FIG. 21B illustrates a diagram of a resistance circuit of an inhaler embodiment of FIG. 21A used for measuring the resistance and pressure of the device.
- FIG. 22 depicts a linear regression plot illustrating the resistance measured through an exemplary cartridge rig tested or R3, at flow rates between 2 and 9 liters/min.
- dry powder inhalation systems for delivering pharmaceutical medicaments to the pulmonary circulation.
- the inhalation systems comprise a breath-powered or breath activated, dry powder inhaler, one or more cartridges containing a pharmaceutical formulation comprising one or more pharmaceutically active substances or active ingredients, and a pharmaceutically acceptable carrier.
- dry powder inhaler 100 comprises housing 102 , and removable mouthpiece assembly or subassembly 104 .
- FIG. 1 illustrates dry powder inhaler 100 in a closed or storage position, wherein mouthpiece oral placement section 106 (illustrated in FIG. 2 ) is stowed away under cover 108 .
- FIG. 1 also illustrates cover or lid 110 over mouthpiece chamber 112 (illustrated in FIG. 2 ). In one embodiment of FIG.
- housing 102 is structurally configured to be relatively rectangular in shape and has top wall 114 , bottom wall 116 , back wall 118 , first side wall 120 , second side wall (not illustrated), mouthpiece engaging section 122 , mouthpiece storage section 124 , and an air intake section as part of housing 102 .
- FIG. 2 illustrates dry powder inhaler 100 from FIG. 1 , showing the inhaler in a cartridge loading/unloading position with lid 110 open to allow a mating cartridge to be inserted into the central cavity of mouthpiece chamber 112 .
- FIG. 2 also illustrates removable mouthpiece subassembly 104 is movable from the storage position in the housing to about 90° relative to longitudinal x-axis 202 of housing 102 rotated about y-axis 204 .
- the cartridge loading/unloading position of mouthpiece assembly 104 can be any predetermined angle as desired. As illustrated in FIG.
- mouthpiece engaging section 122 of housing 102 is relatively circular in shape on the side wall and is shorter in height compared to the rest of housing 102 to accommodate mouthpiece chamber 112 and can form one end of inhaler 100 .
- Housing 102 can also comprise an air conduit with one or more first openings to allow ambient air intake and a second opening in communication with mouthpiece engaging section 122 which allows air flow from the intake section through the conduit into mouthpiece chamber 112 in the inhalation position.
- FIG. 3 depicts dry powder inhaler 100 illustrated in FIG. 1 , showing removable mouthpiece assembly 104 in an extended or inhalation position.
- removable mouthpiece assembly 104 is at about 180° angle relative to the longitudinal x-axis 202 of housing 102 rotated about y-axis 204 .
- the inhalation position of mouthpiece assembly 104 can be varied depending on the structural configuration of the cartridge design to be adapted with the inhaler, and the rotational degrees a cartridge may be rotated to properly align apertures that allow air to enter and exit the cartridge carrying a plume of medicament into mouthpiece exit port 302 .
- FIG. 4 illustrates dry powder inhaler 100 of FIG. 1 showing removable mouthpiece assembly 104 being moveable about the loading/unloading position after use. It should be noted that lid 110 remains closed during movement of removable mouthpiece assembly 104 about housing 102 . FIG. 4 also illustrates mouthpiece oral placement section 106 can be configured with tongue depressor 402 which acts to properly depress the tongue of a user.
- FIG. 5 illustrates dry powder inhaler 100 of FIG. 1 comprising the component parts, removable mouthpiece assembly 104 and housing 102 .
- Removable mouthpiece assembly 104 comprising mouthpiece chamber 112 structurally configured with cartridge holder area 502 , one or more belts 504 and one or more flanges 506 , lid 110 and air inlet port 508 which communicates with the housing second opening to engage with mouthpiece engaging section 122 of housing 102 ; mouthpiece oral placement section 106 extending from mouthpiece chamber 112 and having air inlet port 508 which communicates with mouthpiece chamber 112 and mouthpiece exit port 302 which is in communication with ambient air.
- Drive key 510 structurally configured to have indicator 512 , for example, in the shape of a tear drop for proper placement of a cartridge in dry powder inhaler 100 is also shown in FIG. 2 and FIG. 5 .
- indicator 512 for example, in the shape of a tear drop for proper placement of a cartridge in dry powder inhaler 100 is also shown in FIG. 2 and FIG. 5 .
- Proper alignment of a cartridge in the inhaler indicates the correct relative rotational orientation and determines successful cartridge seating, insertion and emptying in use. In such an embodiment, a cartridge cannot be properly seated unless tear drop 1602 of cartridge 1600 ( FIG. 11 ) and drive key 510 align with one another.
- Lid 110 is positioned over mouthpiece chamber 112 and is mechanically connected to removable mouthpiece assembly 104 by hinge 514 .
- Lid 110 has an outer surface and an inner surface and it is structurally configured with an anvil in its inner top surface and relatively centered within the top. Lid 110 can only be opened when removable mouthpiece assembly 104 is in the loading/unloading position.
- an interlocking mechanism prevents movement to a dosing/inhalation position or to a storage position when lid 110 is opened or raised.
- the interlocking mechanism can comprise, for example, one or more belts or flexible radial arms, which are incorporated into the walls of mouthpiece chamber 112 and act as a self-synching mechanism 602 in FIG. 6 .
- the interlocking mechanism allows removable mouthpiece assembly 104 to obtain proper registration of the various positions when dry powder inhaler 100 is in use.
- Lid 110 can be maintained in a closed position by a locking mechanism, for example, a spring loaded boss such as a lock-out button which can engage a receiving detent within housing 102 .
- the locking mechanism comprises an upward extension of the housing wall.
- the locking mechanism 602 can also serve to secure the mouthpiece subassembly against further rotation. Position registration of removable mouthpiece assembly 104 allows the inhaler to be properly used and prevents movement of removable mouthpiece assembly 104 to the dosing position without lid 110 being depressed.
- FIG. 5 also illustrates housing 102 separated from removable mouthpiece assembly 104 showing mouthpiece engaging section 122 having an opening or cavity 516 with top wall 114 partially discontinuous to adapt, receive and hold removable mouthpiece assembly 104 and structurally configured to accommodate the mouthpiece.
- Housing 102 is configured to have an upward projection of the wall or second flange 518 around the top outer portion of mouthpiece engaging section 122 and a protrusion configured as a drive key in its bottom wall configured to mate with a keying structure of a cartridge.
- the proper alignment of a cartridge within dry powder inhaler 100 is dependent on drive key 510 having an indicator 512 and one or more indentation 126 ( FIG. 2 ) in removable mouthpiece assembly 104 and drive key 510 and of housing 102 .
- Housing 102 comprises mouthpiece engaging section 122 having an outer wall, an inner wall and a bottom wall contiguous with the side and bottom walls respective of housing 102 , and configured to adapt to the mixing section of removable mouthpiece assembly 104 .
- FIG. 6 illustrates a parallel cross-section through the mid-longitudinal plane of housing 102 containing a portion of mouthpiece chamber 112 .
- FIG. 6 also illustrates interlocking mechanism 604 (belts 504 in FIG. 5 ); chamber inner wall 606 defining a space for housing a cartridge.
- Circular structure or plug 608 is the wall of the air conduit of housing 102 which is continuous with back wall 118 of housing 102 .
- FIG. 7 illustrates a cross sectional view of dry powder inhaler 100 in a dosing or inhalation position.
- housing 102 has a substantially rectangular shape, however other shapes are also suitable.
- Housing 102 comprises one or more inlet ports or first openings 702 , air conduit 704 , housing piston 706 and spring 708 , and outlet port 710 opening into mouthpiece engaging section 122 and aligns with the inlet port of mouthpiece chamber 112 .
- Air conduit 704 has one or more openings 712 that allow airflow to enter.
- Mouthpiece engaging section 122 is partially configured in the shape of a cup further comprising second drive key 802 as seen in FIG. 8 from bottom wall 116 configured to receive and hold a medicament containing cartridge.
- FIG. 7 also shows the engagement between flange 506 of mouthpiece chamber 112 in housing 102 ; hinge 514 , lid 110 and mouthpiece oral placement section 106 with tongue depressor 402 and airflow conduit 714 of removable mouthpiece assembly 104 .
- FIG. 8 depicts an exploded view of housing 102 illustrating integral components of dry powder inhaler 100 , including plug 608 , piston 706 and spring 708 which assemble into air conduit 704 ; housing 102 outer structure comprising back wall 118 , side wall 120 , top wall 114 , and bottom wall 116 ; mouthpiece engaging section 122 with second drive key 802 , and slide door 804 which covers the storage compartment for mouthpiece oral placement section 106 .
- Air conduit 704 is configured to have an aperture or opening 712 which allows and directs airflow entering housing 102 into mouthpiece engaging section 122 during an inspiratory maneuver.
- Mouthpiece engaging section 122 can also comprise a securing mechanism which can comprise protrusions or projections from the inner wall of the chamber which mates with flange 506 and mating structure 902 as seen in FIG. 9 of mouthpiece chamber 112 .
- piston 706 and compression spring 708 act as an indicator mechanism positioned in air conduit 704 of housing 102 structurally configured to indicate inspiratory effort.
- Piston 706 and spring 708 can be placed at other positions in the airflow pathway of dry powder inhaler 100 .
- airflow entering the air conduit 704 within housing 102 goes around piston 706 , and moves piston 706 to compress spring 708 .
- This airflow control mechanism during inhalation indicates inspiratory effort through a tactile sensation.
- the mechanism indicates inspiratory effort through an audible click. In another embodiment, the mechanism indicates inspiratory effort through a tactile sensation and/or an audible click. Mouthpiece engaging section 122 of housing 102 has one or more protrusions such as mating structures 902 that mates with mouthpiece chamber 112 to secure mouthpiece when dry powder inhaler 100 is in use.
- removable mouthpiece assembly 104 is rotated from a storage position to a cartridge loading/unloading position wherein lid 110 is opened and a cartridge containing medicament is placed into mouthpiece chamber 112 and securely seated.
- Lid 110 contains an anvil 1102 ( FIG. 11 ) inside which, if a cartridge is inserted in the correct position, the anvil will further insure the cartridge achieves a proper vertical alignment.
- a downward push of lid 110 closes the cover and removable mouthpiece assembly 104 can rotate to the dosing position, wherein a registration securement holds removable mouthpiece assembly 104 in place. If the proper vertical alignment is not achieved lid 110 cannot be fully closed and subsequent removable mouthpiece assembly 104 rotation cannot occur. This provides an interlock mechanism.
- FIG. 9 illustrates removable mouthpiece assembly 104 which has been separated from housing 102 .
- Removable mouthpiece assembly 104 comprises mouthpiece chamber 112 , lid 110 articulated to removable mouthpiece assembly 104 so that in a closed position lid 110 covers mouthpiece chamber 112 , and mouthpiece oral placement section 106 having airflow conduit 714 with mouthpiece exit port 302 .
- Mouthpiece chamber 112 comprises air inlet port 508 , one or more flanges 506 having gaps and mating structure 902 for mating with and securing removable mouthpiece assembly 104 with housing 102 .
- Flange 506 positioned at the bottom end of mouthpiece chamber 112 is provided which is structurally configured to engage with housing 102 , and comprises multiple segments having gaps in between the segments; the gaps section contains mating structure 902 for mating with housing 102 .
- the multiple segments of flange 506 and gaps between the segments can be position at predetermined positions of mouthpiece chamber 112 to effectuate proper securement of removable mouthpiece assembly 104 in housing 102 .
- FIG. 10 is an exploded view of removable mouthpiece assembly 104 .
- Mouthpiece chamber 112 comprises drive key 510 with indicator 512 , lid 110 , mouthpiece oral placement section 106 , cartridge securing mechanism 1002 , a radial spring 1004 , one or more belts 504 and interlock detents 1006 .
- dry powder inhaler 100 is structurally configured to effectuate a tunable airflow resistance, which is modular.
- the resistance of dry powder inhaler 100 can be modified, by varying the cross-sectional area at any section of air conduit 704 of the inhaler.
- dry powder inhaler 100 can have a airflow resistance value of from about 0.08 to about 0.13 square root of kPa/liters per minute.
- dry powder inhaler 100 comprises alternate housing 1104 configured to be compact and comprises a square-shape configuration which snuggly fits with removable mouthpiece assembly 104 .
- Removable mouthpiece assembly 104 is similar in structure, if not identical in some embodiments, to the embodiment described with respect to FIGS. 1-10 .
- FIG. 11 depicts alternate dry powder inhaler 1100 in the cartridge load/unload position with lid 110 open, mouthpiece oral placement section 106 , mouthpiece exit port 302 , anvil 1102 , mouthpiece chamber 112 and interlocking mechanism 604 ( FIG. 6 ).
- Cartridge 1600 has tear drop 1602 indicator for aligning to the indicator 512 of mouthpiece chamber 112 for proper insertion.
- Alternate housing 1104 in this embodiment has an air inlet located in one of the side walls; however, in alternate embodiments the air inlet can be one or more holes placed in other positions, for example, in alternate housing back wall 1106 .
- Alternate dry powder inhaler 1100 can have one or more openings in the housing of variable size or shape and locations.
- Cartridges such as cartridge 1600 can be adapted to the dry powder inhaler containing a dry powder medicament for inhalation, and are configured to deliver a single unit dose of a medicament.
- cartridge 1600 can be structurally configured to contain a dose of, for example, 0.5 mg to about 30 mg of dry powder for inhalation.
- FIG. 12 illustrates an alternate dry powder inhaler 1100 with cartridge 1600 loaded and ready for closure of lid 110 .
- lid 110 is in the open position, mouthpiece chamber 112 and alternate housing 1104 with alternate air inlet 1202 .
- FIG. 13 depicts the dry powder inhaler system of FIG. 12 in the dosing position and ready for inhalation.
- FIG. 14 depicts a cross-section of alternate dry powder inhaler 1100 of FIG. 13 , showing the internal features of the inhaler and cartridge system.
- Lid 110 securely holds cartridge 1600 by way of anvil 1102 , which is then securely installed in mouthpiece chamber 112 .
- dry powder inhaler 100 comprises a removable mouthpiece assembly 104 comprising lid 110 over cartridge holder area 502 movable from a closed to an open position, having anvil 1102 which engages with cartridge 1600 in a closed position, wherein the housing further comprises an air flow control mechanism comprising check valve 1502 .
- the dry powder inhaler system in use has a predetermined airflow distribution around and through a cartridge operably configured to mix a medicament with air forming a powder plume for delivery to a patient's pulmonary system.
- Predetermined airflow distribution through the cartridge can range from about 10 to about 30% of total airflow volume entering the dry powder inhaler during inhalation.
- Predetermined airflow distribution around the cartridge can range from about 70 to about 90% of total airflow volume.
- Predetermined cartridge bypass airflow and exiting airflow through the cartridge converge to further shear and deagglomerate the powder medicament prior to exiting the mouthpiece outlet port.
- the medicament containing cartridge 1600 as shown in FIGS. 16-18 can comprise a structure with a defined shape having a wall with one or more first apertures 1604 , second aperture 1702 and third aperture 1802 , tear drop 1602 , grasping feature 1606 , and first inhaler keying mechanism 1608 and second inhaler keying mechanism 1610 .
- Cartridge 1600 has a closed configuration moveable to an open configuration for dosing a powder medicament or from an open to a closed position after use.
- Cartridge 1600 further comprises an outer surface and an inner surface defining an internal volume; wherein the closed configuration restricts communication, such as air transit to or through the internal volume, and the open configuration forms an air passage through the internal volume to allow a powder medicament contained therein to be aerosolized and delivered to a patient in an airflow stream created by the user.
- the open configuration is established by providing one or more apertures (e.g. first aperture 1604 , second aperture 1702 and third aperture 1802 ), holes, slits or windows in the cartridge walls that can have beveled edges to direct airflow.
- cartridge 1600 can be configured of two elemental parts, for example, two segments (e.g.
- cartridge 1600 can be structurally configured as two separate elements which can fit into one another and be moveable about one another; each having openings which can align with one another, similarly as the capsules described in U.S. Pat. No. 7,305,986, which is fully incorporated herein by reference as if part of this specification.
- cartridge 1600 is designed to integrally function with the dry powder inhaler and can be moved within the inhaler to predetermined positions
- a method of delivering an active ingredient comprising: a) providing a dry powder inhaler comprising, a housing and a mouthpiece, the mouthpiece comprising a chamber containing a cartridge with a dry powder formulation comprising a diketopiperazine and the active agent; the inhaler having a flow distribution of about 10% to 30% of the airflow going through the cartridge, and b) delivering the active ingredient to an individual in need of treatment by inhaling deep and rapidly for about 4 to 6 seconds and optionally repeating step b).
- the dry powder inhaler can deliver a dose of a dry powder formulation to a patient at pressure differentials between 2 and 20 kPa.
- the method of treating hyperglycemia and/or diabetes comprises the administration of an inhalable dry powder composition comprising a diketopiperazine having the formula 2,5-diketo-3,6-di(4-X-aminobutyl)piperazine, wherein X is selected from the group consisting of succinyl, glutaryl, maleyl, and fumaryl.
- the dry powder composition can comprise a diketopiperazine salt.
- diketopiperazine is 2,5-diketo-3,6-di-(4-fumaryl-aminobutyl)piperazine (FDKP), having the structure:
- the inhalation system comprises a breath-activated dry powder inhaler, a cartridge containing medicament, wherein the medicament can comprise a diketopiperazine and an active agent.
- the active agent comprises peptides and proteins.
- the inhalation system comprises a cartridge containing medicament wherein the peptide or protein can be an endocrine hormone, including, insulin, GLP-1, calcitonin, parathyroid hormone, parathyroid hormone related protein (PTHrP), and analogs thereof and the like.
- the dry powder medicament may comprise a diketopiperazine and a pharmaceutically active ingredient.
- the pharmaceutically active ingredient can be any type.
- the active ingredient comprises a peptide, a protein, a hormone, analogs thereof or combinations thereof, wherein the active ingredient is insulin, parathyroid hormone 1-34, glucagon-like peptide-1 (GLP-1), oxyntomodulin, peptide YY, interleukin 2-inducible tyrosine kinase, Bruton's tyrosine kinase (BTK), inositol-requiring kinase 1 (IRE1), heparin, or analogs thereof.
- the pharmaceutical composition comprises fumaryl diketoperazine and insulin.
- the dry powder inhalation system can comprise a cartridge including a formulation for pulmonary delivery comprising FDKP and a peptide including, for example, insulin or GLP-1, which can be provided for use in different dosage strength in a single or multiple cartridges.
- the system can deliver the dosage efficiently, with consistency and in a linear manner.
- multiple cartridges of a single dose to be administered to a subject can be interchangeably replaced or substituted by a providing the system with a single cartridge having the sum of the dosage strength of the multiple cartridges.
- the system can deliver a proportional, bioequivalent dose with a single cartridge.
- the system can use two 15 U cartridges of an inhalation powder comprising insulin and FDKP or the system can use one 30 U single cartridge containing an inhalation powder comprising FDKP and deliver bioequivalent doses of insulin to a patient.
- the system can be used to deliver higher doses, for example, three 15 U cartridges of an inhalation powder comprising insulin and FDKP can be used, or one 15 U cartridge plus one 30 U cartridge, or a single 45 U cartridge containing the inhalable insulin and FDKP formulation; or four 15 U cartridges of an insulin and FDKP formulation can be interchangeable with one 60 U cartridge of insulin and FDKP formulation.
- two 30 U cartridges containing an inhalable insulin and FDKP formulation can be interchanged for one 60 U cartridge of the insulin and FDKP formulation.
- the dry powder inhalation system accomplishes insulin exposure proportional to a dosage so that the dosages are interchangeable.
- the dosage can be provided as filled dose.
- a phase I, open-label, single-dose, repeat administration study in subjects with type 1 diabetes (T1DM) was conducted to assess the pharmacokinetic profile or PK of 30 U of insulin-FDKP dosed as a single 30 U cartridge and compared to two 15 U cartridges administered with the present inhalation system.
- Subjects (age: 19-61 yrs) were randomized to 1 of 6 sequences. Fasted subjects received insulin-FDKP or RAA 4 to 6 hrs after initiating a hyperinsulinemic-euglycemic clamp.
- Randomization determined the order of insulin-FDKP dosing (first 2 treatment (tx) visits), and the location of the RAA injection (abdomen, arm or leg; 3 rd tx visit). After dosing blood samples were taken and analyzed for insulin, insulin lispro and fumaryl diketopiperazine (FDKP (insulin-FDKP tx only)). When studying insulin-FDKP, the basal insulin infusion was performed with HUMALOG®, and when studying HUMALOG®, regular human insulin was used. The analytical methodologies enabled the independent measurement of each insulin tested.
- Table 1 shows the results from the study.
- the mean insulin exposures (AUC 0-360 ) of a single 30 U cartridge or two 15 U cartridges were comparable.
- FDKP mean exposure (AUC inf ) was also similar. Insulin and FDKP exposure, t max and t 1/2 (FDKP) were the same regardless of the number of cartridges. Due to the significantly different PK profiles of insulin-FDKP and RAA, the mean relative exposure (AUC) ratio is dependent upon the time interval studied.
- the mean relative insulin exposure (insulin-FDKP: HUMALOG® AUC, dose normalized geometric means) when assessed at time intervals of 0-180 min and 0-360 min was 24% to 18%.
- FIG. 19 illustrates the results of the GIR evaluation.
- the data show the mean baseline-corrected glucose infusion rate (GIR) for two 15 U cartridges and one 30 U cartridge of insulin-FDKP inhalation powder and for the 10 IU of RAA.
- GIRs after both treatments of insulin-FDKP inhalation powders reached a maximum level by approximately 30 minutes after administration, whereas GIR peaked approximately 150 minutes after administration of sc RAA.
- the GIRs for insulin-FDKP inhalation powder returned toward baseline by approximately 180 minutes versus 300 minutes for RAA.
- the glucose-lowering effect of insulin-FDKP inhalation powder of both dosage forms tested was comparable based on GIR AUC, GIR max , and GIRt max .
- the total inhaler and cartridge resistance can be measured due to inlet and outlet ports of a cartridge acting as resistors in series.
- the resistance due to the inlet port is measured in the cartridge rig.
- the representation of a circuit diagram form for the cartridge rig is illustrated in FIGS. 20A and 20B , wherein the cartridge sits in the holder in an open configuration and the circuitry is defined such that R3 represents the resistance to airflow into the cartridge; R4 represents the resistance to airflow leaving the cartridge; Pa is the pressure differential across the cartridge and P represents the pressure measured across the inlet and outlet ports.
- the resistance due to the inhaler system comprising the inhaler and cartridge is determined as illustrated in FIGS.
- R1 represents the resistance due to the float or valve
- R2 represents the resistance to air flow around the cartridge
- R3 represents the resistance to airflow through the cartridge
- R4 represents the resistance to airflow leaving the cartridge
- P represents the measured pressure
- Pa represents the pressure across the system
- F represents the total flow measurement.
- R3 was determined from the formula:
- the resistance due to the inlet and outlet ports were determined and the values used to calculate the flow balance of the system in particular the flow balance through the cartridge using the formula above, which is determined as the ⁇ P divided by R3.
- the flow balance distribution through the cartridge for the present inhaler and cartridge system was calculated to be in the range from about 10% to about 30% with an average of approximately 15.92%.
- FIG. 22 depicts a linear regression plot illustrating the resistance measured through an exemplary cartridge rig tested or R3, at flow rates between 2 and 9 liters/min. As shown in FIG. 22 , the resistance through the cartridge (R 2 ) tested was determined as equaling to 0.999 ⁇ kPa/liters per minute.
- the inhalers can be structurally configured to have tunable airflow resistance by varying the cross-sectional area at any section of the airflow pathway of the inhaler and cartridge system.
Abstract
Description
- This application is a continuation of patent application Ser. No. 12/413,405 filed Mar. 27, 2009, which claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application Ser. Nos. 61/040,112 filed Mar. 27, 2008 and 61/143,370 filed Jan. 8, 2009; the contents of each of these applications are incorporated by reference herein in their entirety.
- A pulmonary drug delivery system is disclosed. The system includes a dry powder inhaler; and a unit dose cartridge for using with the inhaler. The cartridge can contain a drug delivery formulation for pulmonary delivery, for example, a formulation comprising a diketopiperazine and an active ingredient including peptides and proteins such as insulin and glucagon-
like peptide 1. The dry powder inhaler is compact and comprises a housing, and a mouthpiece having a chamber to install the unit dose cartridge containing medicament and can be separated from its housing for ease of cleaning. - All references cited in this specification, and their references, are incorporated by reference herein in their entirety where appropriate for teachings of additional or alternative details, features, and/or technical background.
- Drug delivery systems for the treatment of disease which introduce active ingredients into the circulation are numerous and include oral, transdermal, inhalation, subcutaneous and intravenous administration. Drugs delivered by inhalation are typically delivered using positive pressure relative to atmospheric pressure in air with propellants. Such drug delivery systems deliver drugs as aerosols, nebulized or vaporized. More recently, drug delivery to lung tissue has been achieved with dry powder inhalers. Dry powder inhalers can be breath-activated to deliver drugs by converting drug particles in a carrier into a fine dry powder which is entrained into an airflow and inhaled by the patient. Drugs delivered with the use of a dry powder inhaler can no longer be intended to treat pulmonary disease only, but also specific drugs can be used to treat many conditions, including diabetes and obesity.
- Dry powder inhalers, used to deliver medicaments to the lungs, contain a dose system of a powder formulation usually either in bulk supply or quantified into individual doses stored in unit dose compartments, like hard gelatin capsules or blister packs. Bulk containers are equipped with a measuring system operated by the patient in order to isolate a single dose from the powder immediately before inhalation. Dosing reproducibility requires that the drug formulation is uniform and that the dose can be delivered to the patient with consistent and reproducible results. Therefore, the dosing system must operate to completely discharge all of the formulation effectively during an inspiratory maneuver when the patient is taking his/her dose. Flow properties of the powder formulation, and long term physical and mechanical stability in this respect, are more critical for bulk containers than they are for single unit dose compartments. Good moisture protection can be achieved more easily for unit dose compartments such as blisters, however, foils used to seal the blisters and subsequent drug formulation lose viability with long storage.
- Dry powder inhalers such as those describe in U.S. Pat. No. 7,305,986 and U.S. patent application Ser. No. 10/655,153 (US 20040182387), the disclosures of which are incorporated herein by reference in their entirety for all they disclose regarding dry powder inhalers, can generate primary drug particles or suitable inhalation plumes during an inspiratory maneuver by deagglomerating the powder formulation within a capsule. The amount of fine drug discharged from the inhaler's mouthpiece during inhalation is largely dependent on the interparticulate forces in the powder formulation (between drug and drug particles or between drug and excipient particles) and the efficiency of the airflow as measured by pressure drop and flow rate entering and exiting the dry powder dispenser. The benefits of delivering drugs via the pulmonary circulation are numerous and include, rapid absorption into the arterial circulation, avoidance of drug degradation by liver metabolism, ease of use, i.e., lack of discomfort of administration by other routes of administration.
- Dry powder inhaler products developed for pulmonary inhalation have met with limited success to date, due to lack of practicality. Some of the persistent problems observed with prior art inhalers, include ruggedness of device, inconsistency in dosing, inconvenience of the equipment, and/or lack of patient compliance. Therefore, the inventors have designed and manufactured a dry powder inhaler with consistent drug delivery properties, ease of use without discomfort, improved ruggedness, and discrete geometries which would allow for better patient compliance.
- Dry powder inhaler systems for pulmonary delivery of pharmaceuticals are disclosed. The dry powder inhalation systems comprise a dry powder inhalation device or inhaler and at least one cartridge containing a pharmaceutical formulation comprising at least one active ingredient for delivery to the pulmonary circulation. The present inhalation systems provide rugged devices which are reusable, use pre-metered unit dose cartridges and can be separated into their principal component parts for ease of cleaning. The devices also provide high resistance inhalation systems which enable deagglomeration of dry powder particles, have consistent airflow and are simple and easy to use.
- In one embodiment, a dry powder inhaler comprises a housing, and a mouthpiece, wherein the housing comprises a mouthpiece engaging section structurally configured to engage with the mouthpiece, and the mouthpiece being removable at predetermined positions relative to the housing, and having a conduit permitting airflow between an air inlet and an air exit port, and comprising a chamber and an oral placement section; the mouthpiece further being structurally configured to be moveable within the housing in an engaged position and releasable from the housing at a predetermined position. The dry powder inhaler mouthpiece is structurally configured to receive, hold and/or release a medicament containing cartridge in the chamber.
- In another embodiment, the housing comprises a container structurally configured to adapt to the mouthpiece and has one or more openings for allowing air intake into the mouthpiece chamber. In such an embodiment, the housing has securing mechanisms to hold the mouthpiece chamber and permit the mouthpiece assembly to be moveable within the housing to a storage position, to a cartridge loading/unloading position, mouthpiece separable position, to an inhalation position and in reversed order.
- In still another embodiment, the mouthpiece assembly engages the mouthpiece at the mouthpiece engaging section of the housing. The housing can comprise an air intake section having an air conduit with one or more first openings to allow ambient air intake and a second opening in communication with the mouthpiece engaging section which allows airflow through the air conduit and out into the housing engaging section, the engagement of the mouthpiece substantially prevents ambient air from entering the conduit except at the one or more first openings in the housing for air intake. In one embodiment, the housing also comprises a mouthpiece storage section.
- In yet another embodiment, the dry powder inhaler mouthpiece assembly can move relative to the housing and the movement of the mouthpiece within the housing can reconfigure a cartridge seated in the inhaler from a closed configuration to an open configuration, or from an open to a closed configuration. Movement of the mouthpiece within the housing can be of various types, such as translational or rotational. In one such embodiment, movement about the housing is rotational, and can be restricted at predetermined locations relative to the housing to provide registration of positions of the mouthpiece in use. In one embodiment, for example, movement of the mouthpiece assembly is rotational and the mouthpiece can rotate from the storage position to a cartridge loading/unloading position to an inhalation position. In another embodiment, the mouthpiece further comprises a mouthpiece oral placement section and a medicament containing cartridge receiving section; the cartridge receiving section configured to permit and direct air flow through and around the cartridge.
- In a further embodiment, the air conduit of the air intake section of the housing is in communication with the air exit port of the mouthpiece when the cartridge is in an open configuration. The airflow conduit is established between one or more first openings in the housing; then air passes through the airflow conduit within the housing and exits a second opening of the mouthpiece engaging section and enters into the mouthpiece chamber wherein a percentage of intake air volume goes through the cartridge and a percentage of intake air volume goes around the cartridge during an inhalation maneuver. In this embodiment, the airflow path then enters the mouthpiece chamber and enters and exits the conduit of the mouthpiece oral placement section. In a further embodiment, with a cartridge containing medicament placed in the chamber, airflow entering the chamber from the housing outlet port is diverted so that a percentage of the airflow volume goes through the cartridge and a percentage of the airflow volume goes around the cartridge. Both air flow volumes, exiting the cartridge with a medicament and airflow around the cartridge, converge prior to entering and exiting the air exit port of the mouthpiece of the oral placement section.
- In another embodiment, a dry powder inhaler is provided comprising a housing, and a mouthpiece assembly, the housing having a top wall, a bottom wall, side walls; a mouthpiece engaging section, a mouthpiece storage section, and an air intake section having a conduit with a first opening to allow ambient air intake and a second opening in communication with the mouthpiece engaging section which allows air flow therethrough; the mouthpiece subassembly being removable and comprising a chamber structurally configured to house a cartridge and to engage with the mouthpiece engaging section of the housing; an oral placement section extending from the chamber and having an air inlet which communicates with the chamber and an air outlet in communication with ambient air.
- In embodiments described herewith, a breath-powered inhaler is provided comprising, an inhaler with resistance values that can be tunable or changed as required by the patient being an adult or a child. In one embodiment, the resistance values of the inhaler can be altered by changing the geometries or configuration of the air conduits so that airflow distribution through the cartridge and around the cartridge can vary. In one embodiment, inhaler resistance values can range between 0.08 and 0.15 √kPa/liters per minute. In certain embodiments, flow balance distribution can range from about 10% to about 30% through the cartridge and from about 70% to 90% going around the cartridge.
- In still a further embodiment, the dry powder inhalation system comprises a breath-activated dry powder inhaler, a cartridge containing medicament, wherein the medicament can comprise a diketopiperazine and an active agent. In some embodiments, the active agent comprises peptides and proteins. In another embodiment, the inhalation system comprises a cartridge containing medicament wherein the peptide or protein can be an endocrine hormone: including, insulin, glucose-like peptide (GLP-1), parathyroid hormone, parathyroid hormone related protein (PTHrP), and the like.
- In one embodiment, the dry powder inhalation system can comprise a cartridge including a formulation for pulmonary delivery which can be provided for use with different dosage strengths, wherein the system can deliver the dosage with consistency and in a linear manner. In this embodiment, for example, multiple cartridges of a single dose to be administered to a subject can be interchangeably replaced or substituted by providing the system with a single cartridge of the sum of the dosage strength of the multiple cartridges, wherein the system can deliver a bioequivalent dose with a single cartridge.
-
FIG. 1 illustrates a three dimensional side view of an embodiment of a dry powder inhaler in a storage position. -
FIG. 2 illustrates the back side view of the dry powder inhaler ofFIG. 1 showing the mouthpiece subassembly moved from the storage position to a cartridge loading position wherein the cap is opened. In this embodiment, this is also the position at which the mouthpiece can be separated. -
FIG. 3 illustrates the back side view of the dry powder inhaler ofFIG. 1 showing the mouthpiece subassembly has been moved to the inhalation position for use. -
FIG. 4 illustrates the back side view of the dry powder inhaler ofFIG. 1 showing the mouthpiece subassembly has been moved to an unloading position after inhalation. -
FIG. 5 illustrates the dry powder inhaler ofFIG. 1 , showing the housing subassembly and the mouthpiece subassembly disengaged from one another. -
FIG. 6 illustrates a top view section of a housing subassembly of a dry powder inhaler. -
FIG. 7 illustrates the dry powder inhaler shown inFIG. 3 in cross-section. -
FIG. 8 illustrates the dry powder inhaler ofFIG. 1 , showing an exploded view of the housing subassembly. -
FIG. 9 illustrates the dry powder inhaler ofFIG. 1 , showing the mouthpiece subassembly removed from the housing component. -
FIG. 10 illustrates the dry powder inhaler ofFIG. 1 , showing an exploded view of the mouthpiece subassembly. -
FIG. 11 illustrates an alternate embodiment of the dry powder inhaler system showing the inhaler in a cartridge loading position.FIG. 11 also depicts a cartridge embodiment for use with a dry powder inhaler according to the present description. -
FIG. 12 illustrates the embodiment ofFIG. 11 with a cartridge loaded into the dry powder inhaler with the cap open. -
FIG. 13 illustrates the embodiment ofFIG. 11 showing the dry powder inhaler in an inhalation position. -
FIG. 14 illustrates the embodiment ofFIG. 13 showing the dry powder inhaler in inhalation position as a cross-section through the mid-longitudinal axis. -
FIG. 15 illustrates a cross-section of an embodiment wherein the dry powder inhaler is shown in the dosing position and containing a cartridge. -
FIG. 16 illustrates an embodiment of a three dimensional side view of a cartridge for use with the dry powder inhalation system. -
FIG. 17 illustrates an embodiment of a three dimensional back side view cartridge for use with the dry powder inhalation system. -
FIG. 18 illustrates an embodiment of an exploded three dimensional view of the cartridge for use with the dry powder inhalation system. -
FIG. 19 illustrates a mean baseline-corrected GIR (glucose infusion rate) for two 15 U cartridges and one 30 U cartridge of an inhalation powder comprising insulin and fumaryl diketopiperazine, and for 10 IU of RAA. -
FIG. 20A depicts a schematic representation of a cartridge loaded into a cartridge rig in cross-section for measuring pressure across the cartridge.FIG. 20B illustrates a diagram of a resistance circuit illustrating the various resistors associated with the cartridge rig illustrated inFIG. 20A . -
FIG. 21A illustrates a schematic representation of a portion of the inhaler in cross-section showing components parts.FIG. 21B illustrates a diagram of a resistance circuit of an inhaler embodiment ofFIG. 21A used for measuring the resistance and pressure of the device. -
FIG. 22 depicts a linear regression plot illustrating the resistance measured through an exemplary cartridge rig tested or R3, at flow rates between 2 and 9 liters/min. - In embodiments disclosed herein, there are disclosed dry powder inhalation systems for delivering pharmaceutical medicaments to the pulmonary circulation. The inhalation systems comprise a breath-powered or breath activated, dry powder inhaler, one or more cartridges containing a pharmaceutical formulation comprising one or more pharmaceutically active substances or active ingredients, and a pharmaceutically acceptable carrier.
- One embodiment of a dry powder inhaler is shown in
FIG. 1 . Therein,dry powder inhaler 100 compriseshousing 102, and removable mouthpiece assembly orsubassembly 104.FIG. 1 illustratesdry powder inhaler 100 in a closed or storage position, wherein mouthpiece oral placement section 106 (illustrated inFIG. 2 ) is stowed away undercover 108.FIG. 1 also illustrates cover orlid 110 over mouthpiece chamber 112 (illustrated inFIG. 2 ). In one embodiment ofFIG. 1 ,housing 102 is structurally configured to be relatively rectangular in shape and hastop wall 114,bottom wall 116,back wall 118,first side wall 120, second side wall (not illustrated),mouthpiece engaging section 122,mouthpiece storage section 124, and an air intake section as part ofhousing 102. -
FIG. 2 illustratesdry powder inhaler 100 fromFIG. 1 , showing the inhaler in a cartridge loading/unloading position withlid 110 open to allow a mating cartridge to be inserted into the central cavity ofmouthpiece chamber 112.FIG. 2 also illustratesremovable mouthpiece subassembly 104 is movable from the storage position in the housing to about 90° relative tolongitudinal x-axis 202 ofhousing 102 rotated about y-axis 204. In certain embodiments, the cartridge loading/unloading position ofmouthpiece assembly 104 can be any predetermined angle as desired. As illustrated inFIG. 2 ,mouthpiece engaging section 122 ofhousing 102 is relatively circular in shape on the side wall and is shorter in height compared to the rest ofhousing 102 to accommodatemouthpiece chamber 112 and can form one end ofinhaler 100. Housing 102 can also comprise an air conduit with one or more first openings to allow ambient air intake and a second opening in communication withmouthpiece engaging section 122 which allows air flow from the intake section through the conduit intomouthpiece chamber 112 in the inhalation position. -
FIG. 3 depictsdry powder inhaler 100 illustrated inFIG. 1 , showingremovable mouthpiece assembly 104 in an extended or inhalation position. In this embodiment,removable mouthpiece assembly 104 is at about 180° angle relative to thelongitudinal x-axis 202 ofhousing 102 rotated about y-axis 204. In some embodiments, the inhalation position ofmouthpiece assembly 104 can be varied depending on the structural configuration of the cartridge design to be adapted with the inhaler, and the rotational degrees a cartridge may be rotated to properly align apertures that allow air to enter and exit the cartridge carrying a plume of medicament intomouthpiece exit port 302. -
FIG. 4 illustratesdry powder inhaler 100 ofFIG. 1 showingremovable mouthpiece assembly 104 being moveable about the loading/unloading position after use. It should be noted thatlid 110 remains closed during movement ofremovable mouthpiece assembly 104 abouthousing 102.FIG. 4 also illustrates mouthpieceoral placement section 106 can be configured withtongue depressor 402 which acts to properly depress the tongue of a user. -
FIG. 5 illustratesdry powder inhaler 100 ofFIG. 1 comprising the component parts,removable mouthpiece assembly 104 andhousing 102.Removable mouthpiece assembly 104 comprisingmouthpiece chamber 112 structurally configured withcartridge holder area 502, one ormore belts 504 and one ormore flanges 506,lid 110 andair inlet port 508 which communicates with the housing second opening to engage withmouthpiece engaging section 122 ofhousing 102; mouthpieceoral placement section 106 extending frommouthpiece chamber 112 and havingair inlet port 508 which communicates withmouthpiece chamber 112 andmouthpiece exit port 302 which is in communication with ambient air. Drive key 510 structurally configured to haveindicator 512, for example, in the shape of a tear drop for proper placement of a cartridge indry powder inhaler 100 is also shown inFIG. 2 andFIG. 5 . Proper alignment of a cartridge in the inhaler indicates the correct relative rotational orientation and determines successful cartridge seating, insertion and emptying in use. In such an embodiment, a cartridge cannot be properly seated unlesstear drop 1602 of cartridge 1600 (FIG. 11 ) and drive key 510 align with one another. -
Lid 110 is positioned overmouthpiece chamber 112 and is mechanically connected toremovable mouthpiece assembly 104 byhinge 514.Lid 110 has an outer surface and an inner surface and it is structurally configured with an anvil in its inner top surface and relatively centered within the top.Lid 110 can only be opened whenremovable mouthpiece assembly 104 is in the loading/unloading position. Whenremovable mouthpiece assembly 104 is engaged intohousing 102 an interlocking mechanism prevents movement to a dosing/inhalation position or to a storage position whenlid 110 is opened or raised. The interlocking mechanism can comprise, for example, one or more belts or flexible radial arms, which are incorporated into the walls ofmouthpiece chamber 112 and act as a self-synchingmechanism 602 inFIG. 6 . The interlocking mechanism allowsremovable mouthpiece assembly 104 to obtain proper registration of the various positions whendry powder inhaler 100 is in use.Lid 110 can be maintained in a closed position by a locking mechanism, for example, a spring loaded boss such as a lock-out button which can engage a receiving detent withinhousing 102. In an alternate embodiment, the locking mechanism comprises an upward extension of the housing wall. Thelocking mechanism 602 can also serve to secure the mouthpiece subassembly against further rotation. Position registration ofremovable mouthpiece assembly 104 allows the inhaler to be properly used and prevents movement ofremovable mouthpiece assembly 104 to the dosing position withoutlid 110 being depressed. -
FIG. 5 also illustrateshousing 102 separated fromremovable mouthpiece assembly 104 showingmouthpiece engaging section 122 having an opening orcavity 516 withtop wall 114 partially discontinuous to adapt, receive and holdremovable mouthpiece assembly 104 and structurally configured to accommodate the mouthpiece.Housing 102 is configured to have an upward projection of the wall orsecond flange 518 around the top outer portion ofmouthpiece engaging section 122 and a protrusion configured as a drive key in its bottom wall configured to mate with a keying structure of a cartridge. The proper alignment of a cartridge withindry powder inhaler 100 is dependent ondrive key 510 having anindicator 512 and one or more indentation 126 (FIG. 2 ) inremovable mouthpiece assembly 104 and drive key 510 and ofhousing 102. -
Housing 102 comprisesmouthpiece engaging section 122 having an outer wall, an inner wall and a bottom wall contiguous with the side and bottom walls respective ofhousing 102, and configured to adapt to the mixing section ofremovable mouthpiece assembly 104.FIG. 6 illustrates a parallel cross-section through the mid-longitudinal plane ofhousing 102 containing a portion ofmouthpiece chamber 112.FIG. 6 also illustrates interlocking mechanism 604 (belts 504 inFIG. 5 ); chamberinner wall 606 defining a space for housing a cartridge. Circular structure or plug 608 is the wall of the air conduit ofhousing 102 which is continuous withback wall 118 ofhousing 102. -
FIG. 7 illustrates a cross sectional view ofdry powder inhaler 100 in a dosing or inhalation position. As seen inFIG. 7 ,housing 102 has a substantially rectangular shape, however other shapes are also suitable.Housing 102 comprises one or more inlet ports orfirst openings 702,air conduit 704,housing piston 706 andspring 708, andoutlet port 710 opening intomouthpiece engaging section 122 and aligns with the inlet port ofmouthpiece chamber 112.Air conduit 704 has one ormore openings 712 that allow airflow to enter. -
Mouthpiece engaging section 122 is partially configured in the shape of a cup further comprisingsecond drive key 802 as seen inFIG. 8 frombottom wall 116 configured to receive and hold a medicament containing cartridge.FIG. 7 also shows the engagement betweenflange 506 ofmouthpiece chamber 112 inhousing 102; hinge 514,lid 110 and mouthpieceoral placement section 106 withtongue depressor 402 andairflow conduit 714 ofremovable mouthpiece assembly 104. -
FIG. 8 depicts an exploded view ofhousing 102 illustrating integral components ofdry powder inhaler 100, includingplug 608,piston 706 andspring 708 which assemble intoair conduit 704;housing 102 outer structure comprising backwall 118,side wall 120,top wall 114, andbottom wall 116;mouthpiece engaging section 122 withsecond drive key 802, and slidedoor 804 which covers the storage compartment for mouthpieceoral placement section 106.Air conduit 704 is configured to have an aperture oropening 712 which allows and directsairflow entering housing 102 intomouthpiece engaging section 122 during an inspiratory maneuver.Mouthpiece engaging section 122 can also comprise a securing mechanism which can comprise protrusions or projections from the inner wall of the chamber which mates withflange 506 andmating structure 902 as seen inFIG. 9 ofmouthpiece chamber 112. In this embodiment,piston 706 andcompression spring 708 act as an indicator mechanism positioned inair conduit 704 ofhousing 102 structurally configured to indicate inspiratory effort.Piston 706 andspring 708 can be placed at other positions in the airflow pathway ofdry powder inhaler 100. During an inspiratory maneuver, airflow entering theair conduit 704 withinhousing 102 goes aroundpiston 706, and movespiston 706 to compressspring 708. This airflow control mechanism during inhalation indicates inspiratory effort through a tactile sensation. In one embodiment, the mechanism indicates inspiratory effort through an audible click. In another embodiment, the mechanism indicates inspiratory effort through a tactile sensation and/or an audible click.Mouthpiece engaging section 122 ofhousing 102 has one or more protrusions such asmating structures 902 that mates withmouthpiece chamber 112 to secure mouthpiece whendry powder inhaler 100 is in use. - In operation,
removable mouthpiece assembly 104 is rotated from a storage position to a cartridge loading/unloading position whereinlid 110 is opened and a cartridge containing medicament is placed intomouthpiece chamber 112 and securely seated.Lid 110 contains an anvil 1102 (FIG. 11 ) inside which, if a cartridge is inserted in the correct position, the anvil will further insure the cartridge achieves a proper vertical alignment. A downward push oflid 110 closes the cover andremovable mouthpiece assembly 104 can rotate to the dosing position, wherein a registration securement holdsremovable mouthpiece assembly 104 in place. If the proper vertical alignment is not achievedlid 110 cannot be fully closed and subsequentremovable mouthpiece assembly 104 rotation cannot occur. This provides an interlock mechanism. -
FIG. 9 illustratesremovable mouthpiece assembly 104 which has been separated fromhousing 102.Removable mouthpiece assembly 104 comprisesmouthpiece chamber 112,lid 110 articulated toremovable mouthpiece assembly 104 so that in aclosed position lid 110covers mouthpiece chamber 112, and mouthpieceoral placement section 106 havingairflow conduit 714 withmouthpiece exit port 302.Mouthpiece chamber 112 comprisesair inlet port 508, one ormore flanges 506 having gaps andmating structure 902 for mating with and securingremovable mouthpiece assembly 104 withhousing 102.Flange 506 positioned at the bottom end ofmouthpiece chamber 112 is provided which is structurally configured to engage withhousing 102, and comprises multiple segments having gaps in between the segments; the gaps section containsmating structure 902 for mating withhousing 102. The multiple segments offlange 506 and gaps between the segments can be position at predetermined positions ofmouthpiece chamber 112 to effectuate proper securement ofremovable mouthpiece assembly 104 inhousing 102. -
FIG. 10 is an exploded view ofremovable mouthpiece assembly 104.Mouthpiece chamber 112 comprises drive key 510 withindicator 512,lid 110, mouthpieceoral placement section 106,cartridge securing mechanism 1002, aradial spring 1004, one ormore belts 504 andinterlock detents 1006. - In embodiments described herein,
dry powder inhaler 100 is structurally configured to effectuate a tunable airflow resistance, which is modular. The resistance ofdry powder inhaler 100 can be modified, by varying the cross-sectional area at any section ofair conduit 704 of the inhaler. In one embodiment,dry powder inhaler 100 can have a airflow resistance value of from about 0.08 to about 0.13 square root of kPa/liters per minute. - In an alternate embodiment illustrated in
FIGS. 11-14 ,dry powder inhaler 100 comprises alternate housing 1104 configured to be compact and comprises a square-shape configuration which snuggly fits withremovable mouthpiece assembly 104.Removable mouthpiece assembly 104 is similar in structure, if not identical in some embodiments, to the embodiment described with respect toFIGS. 1-10 .FIG. 11 depicts alternatedry powder inhaler 1100 in the cartridge load/unload position withlid 110 open, mouthpieceoral placement section 106,mouthpiece exit port 302,anvil 1102,mouthpiece chamber 112 and interlocking mechanism 604 (FIG. 6 ).Cartridge 1600 hastear drop 1602 indicator for aligning to theindicator 512 ofmouthpiece chamber 112 for proper insertion. Alternate housing 1104 in this embodiment, has an air inlet located in one of the side walls; however, in alternate embodiments the air inlet can be one or more holes placed in other positions, for example, in alternatehousing back wall 1106. Alternatedry powder inhaler 1100 can have one or more openings in the housing of variable size or shape and locations. - Cartridges such as
cartridge 1600 can be adapted to the dry powder inhaler containing a dry powder medicament for inhalation, and are configured to deliver a single unit dose of a medicament. In one embodiment,cartridge 1600 can be structurally configured to contain a dose of, for example, 0.5 mg to about 30 mg of dry powder for inhalation. -
FIG. 12 illustrates an alternatedry powder inhaler 1100 withcartridge 1600 loaded and ready for closure oflid 110. As can be seen,lid 110 is in the open position,mouthpiece chamber 112 and alternate housing 1104 withalternate air inlet 1202.FIG. 13 depicts the dry powder inhaler system ofFIG. 12 in the dosing position and ready for inhalation. -
FIG. 14 depicts a cross-section of alternatedry powder inhaler 1100 ofFIG. 13 , showing the internal features of the inhaler and cartridge system.Lid 110 securely holdscartridge 1600 by way ofanvil 1102, which is then securely installed inmouthpiece chamber 112. Theairflow conduit 714 of mouthpieceoral placement section 106 withmouthpiece inlet port 1402 andmouthpiece exit port 302. - In some embodiments, as shown in
FIG. 15 ,dry powder inhaler 100 comprises aremovable mouthpiece assembly 104 comprisinglid 110 overcartridge holder area 502 movable from a closed to an open position, havinganvil 1102 which engages withcartridge 1600 in a closed position, wherein the housing further comprises an air flow control mechanism comprisingcheck valve 1502. - In embodiments described herein, the dry powder inhaler system in use has a predetermined airflow distribution around and through a cartridge operably configured to mix a medicament with air forming a powder plume for delivery to a patient's pulmonary system. Predetermined airflow distribution through the cartridge can range from about 10 to about 30% of total airflow volume entering the dry powder inhaler during inhalation. Predetermined airflow distribution around the cartridge can range from about 70 to about 90% of total airflow volume. Predetermined cartridge bypass airflow and exiting airflow through the cartridge converge to further shear and deagglomerate the powder medicament prior to exiting the mouthpiece outlet port.
- In one embodiment, the
medicament containing cartridge 1600 as shown inFIGS. 16-18 can comprise a structure with a defined shape having a wall with one or morefirst apertures 1604,second aperture 1702 andthird aperture 1802,tear drop 1602, graspingfeature 1606, and firstinhaler keying mechanism 1608 and secondinhaler keying mechanism 1610.Cartridge 1600 has a closed configuration moveable to an open configuration for dosing a powder medicament or from an open to a closed position after use.Cartridge 1600 further comprises an outer surface and an inner surface defining an internal volume; wherein the closed configuration restricts communication, such as air transit to or through the internal volume, and the open configuration forms an air passage through the internal volume to allow a powder medicament contained therein to be aerosolized and delivered to a patient in an airflow stream created by the user. The open configuration is established by providing one or more apertures (e.g.first aperture 1604,second aperture 1702 and third aperture 1802), holes, slits or windows in the cartridge walls that can have beveled edges to direct airflow. In one embodiment,cartridge 1600 can be configured of two elemental parts, for example, two segments (e.g.first segment 1804 and second segment 1806) that can have apertures in their walls that can align with one another in the open configuration and in opposing positions where the apertures at not in alignment. In one embodiment, for example,cartridge 1600 can be structurally configured as two separate elements which can fit into one another and be moveable about one another; each having openings which can align with one another, similarly as the capsules described in U.S. Pat. No. 7,305,986, which is fully incorporated herein by reference as if part of this specification. In this embodiment, however,cartridge 1600 is designed to integrally function with the dry powder inhaler and can be moved within the inhaler to predetermined positions - In one embodiment, a method of delivering an active ingredient comprising: a) providing a dry powder inhaler comprising, a housing and a mouthpiece, the mouthpiece comprising a chamber containing a cartridge with a dry powder formulation comprising a diketopiperazine and the active agent; the inhaler having a flow distribution of about 10% to 30% of the airflow going through the cartridge, and b) delivering the active ingredient to an individual in need of treatment by inhaling deep and rapidly for about 4 to 6 seconds and optionally repeating step b).
- In embodiments described herein, the dry powder inhaler can deliver a dose of a dry powder formulation to a patient at pressure differentials between 2 and 20 kPa.
- In still yet a further embodiment, the method of treating hyperglycemia and/or diabetes comprises the administration of an inhalable dry powder composition comprising a diketopiperazine having the formula 2,5-diketo-3,6-di(4-X-aminobutyl)piperazine, wherein X is selected from the group consisting of succinyl, glutaryl, maleyl, and fumaryl. In this embodiment, the dry powder composition can comprise a diketopiperazine salt. In still yet another embodiment of the present invention, there is provided a dry powder composition, wherein the diketopiperazine is 2,5-diketo-3,6-di-(4-fumaryl-aminobutyl)piperazine (FDKP), having the structure:
- with or without a pharmaceutically acceptable carrier, or excipient.
- In one embodiment, the inhalation system comprises a breath-activated dry powder inhaler, a cartridge containing medicament, wherein the medicament can comprise a diketopiperazine and an active agent. In some embodiments, the active agent comprises peptides and proteins. In another embodiment, the inhalation system comprises a cartridge containing medicament wherein the peptide or protein can be an endocrine hormone, including, insulin, GLP-1, calcitonin, parathyroid hormone, parathyroid hormone related protein (PTHrP), and analogs thereof and the like.
- In another embodiment, the dry powder medicament may comprise a diketopiperazine and a pharmaceutically active ingredient. In this embodiment, the pharmaceutically active ingredient can be any type. In certain embodiments, the active ingredient comprises a peptide, a protein, a hormone, analogs thereof or combinations thereof, wherein the active ingredient is insulin, parathyroid hormone 1-34, glucagon-like peptide-1 (GLP-1), oxyntomodulin, peptide YY, interleukin 2-inducible tyrosine kinase, Bruton's tyrosine kinase (BTK), inositol-requiring kinase 1 (IRE1), heparin, or analogs thereof. In a particular embodiment, the pharmaceutical composition comprises fumaryl diketoperazine and insulin.
- In a particular embodiment, the dry powder inhalation system can comprise a cartridge including a formulation for pulmonary delivery comprising FDKP and a peptide including, for example, insulin or GLP-1, which can be provided for use in different dosage strength in a single or multiple cartridges. In one embodiment, the system can deliver the dosage efficiently, with consistency and in a linear manner. In this embodiment, for example, multiple cartridges of a single dose to be administered to a subject can be interchangeably replaced or substituted by a providing the system with a single cartridge having the sum of the dosage strength of the multiple cartridges. In further embodiment, the system can deliver a proportional, bioequivalent dose with a single cartridge. In an exemplary embodiment using the system for treating diabetes with inhalable insulin powders, the system can use two 15 U cartridges of an inhalation powder comprising insulin and FDKP or the system can use one 30 U single cartridge containing an inhalation powder comprising FDKP and deliver bioequivalent doses of insulin to a patient. Similarly, the system can be used to deliver higher doses, for example, three 15 U cartridges of an inhalation powder comprising insulin and FDKP can be used, or one 15 U cartridge plus one 30 U cartridge, or a single 45 U cartridge containing the inhalable insulin and FDKP formulation; or four 15 U cartridges of an insulin and FDKP formulation can be interchangeable with one 60 U cartridge of insulin and FDKP formulation. Alternatively, two 30 U cartridges containing an inhalable insulin and FDKP formulation can be interchanged for one 60 U cartridge of the insulin and FDKP formulation.
- In the embodiments described herein, the dry powder inhalation system accomplishes insulin exposure proportional to a dosage so that the dosages are interchangeable. In an embodiment, the dosage can be provided as filled dose.
- The following examples are included to demonstrate certain embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples elucidate representative techniques that function well in the practice of the present invention. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments that are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.
- The study was conducted in subjects with
type 1 diabetes mellitus. This study was conducted to determine if a formulation for pulmonary delivery comprising insulin and a diketopiperazine in the formulation, 1) could be delivered consistently using different dosage strengths and 2) if linearity of dosing could be achieved with proportional doses, given that interchangeability of dosage strengths can be important for patient safety. A prior art marketed inhaled insulin did not achieve this and dose combinations were nonequivalent leading to a potential risk of incorrect dosing. Therefore, an important goal in the development of the pulmonary delivery system with a formulation comprising insulin and FDKP (insulin-FDKP) was to achieve dose linearity across the therapeutic dose range. - In the study, comparisons of insulin exposure following inhalation of two 15 U cartridges of an insulin inhalation powder to one 30 U cartridge of insulin inhalation powder were made. In addition, insulin bioavailability from a 30 U cartridge of insulin-FDKP inhalation powder was calculated, compared to a 10-IU subcutaneous (sc) injection of insulin lispro (rapid acting analogue [RAA]).
- A phase I, open-label, single-dose, repeat administration study in subjects with
type 1 diabetes (T1DM) was conducted to assess the pharmacokinetic profile or PK of 30 U of insulin-FDKP dosed as a single 30 U cartridge and compared to two 15 U cartridges administered with the present inhalation system. A 10 U subcutaneous injection of the rapid acting insulin analogue (RAA, HUMALOG® (Eli Lilly and Company, Indianapolis, Ind.)) was also tested. Subjects (age: 19-61 yrs) were randomized to 1 of 6 sequences. Fasted subjects received insulin-FDKP or RAA 4 to 6 hrs after initiating a hyperinsulinemic-euglycemic clamp. Randomization determined the order of insulin-FDKP dosing (first 2 treatment (tx) visits), and the location of the RAA injection (abdomen, arm or leg; 3rd tx visit). After dosing blood samples were taken and analyzed for insulin, insulin lispro and fumaryl diketopiperazine (FDKP (insulin-FDKP tx only)). When studying insulin-FDKP, the basal insulin infusion was performed with HUMALOG®, and when studying HUMALOG®, regular human insulin was used. The analytical methodologies enabled the independent measurement of each insulin tested. - Table 1 shows the results from the study. The mean insulin exposures (AUC0-360) of a single 30 U cartridge or two 15 U cartridges were comparable. FDKP mean exposure (AUCinf) was also similar. Insulin and FDKP exposure, tmax and t1/2 (FDKP) were the same regardless of the number of cartridges. Due to the significantly different PK profiles of insulin-FDKP and RAA, the mean relative exposure (AUC) ratio is dependent upon the time interval studied. The mean relative insulin exposure (insulin-FDKP: HUMALOG® AUC, dose normalized geometric means) when assessed at time intervals of 0-180 min and 0-360 min was 24% to 18%.
-
TABLE 1 2 X 15 U TI 1 X 30 U TI 10 IU cartridges cartridge Humalog Insulin PK parameters AUC0-360 (μU*min/mL) 3337 3397 5915 AUC0-180 (μU*min/mL) 3121 3199 4432 Cmax (μU/mL) 65.72 69.08 42.60 tmax (min) 10 10 60 90% CI (Geometric Mean 0.846, 1.141 ND Ratio: AUC0-360) FDKP PK parameters AUC0-480 (ng*min/mL) 19552 20159 — AUC0-inf (ng*min/mL) 23146 24355 — Cmax (ng/mL) 118 131 — tmax (min) 6 5 — 90% CI(Geometric Mean 0.867, 1.084 — Ratio: AUC0-480) - This study also evaluated the effects of the dosages administered and the glucose infusion rate (GIR) requirements of the patients in the study.
FIG. 19 illustrates the results of the GIR evaluation. The data show the mean baseline-corrected glucose infusion rate (GIR) for two 15 U cartridges and one 30 U cartridge of insulin-FDKP inhalation powder and for the 10 IU of RAA. GIRs after both treatments of insulin-FDKP inhalation powders reached a maximum level by approximately 30 minutes after administration, whereas GIR peaked approximately 150 minutes after administration of sc RAA. The GIRs for insulin-FDKP inhalation powder returned toward baseline by approximately 180 minutes versus 300 minutes for RAA. In conclusion, the glucose-lowering effect of insulin-FDKP inhalation powder of both dosage forms tested was comparable based on GIR AUC, GIRmax, and GIRtmax. - The total inhaler and cartridge resistance can be measured due to inlet and outlet ports of a cartridge acting as resistors in series. First, the resistance due to the inlet port is measured in the cartridge rig. The representation of a circuit diagram form for the cartridge rig is illustrated in
FIGS. 20A and 20B , wherein the cartridge sits in the holder in an open configuration and the circuitry is defined such that R3 represents the resistance to airflow into the cartridge; R4 represents the resistance to airflow leaving the cartridge; Pa is the pressure differential across the cartridge and P represents the pressure measured across the inlet and outlet ports. Secondly, the resistance due to the inhaler system comprising the inhaler and cartridge is determined as illustrated inFIGS. 21A and 21B , wherein R1 represents the resistance due to the float or valve; R2 represents the resistance to air flow around the cartridge; R3 represents the resistance to airflow through the cartridge; R4 represents the resistance to airflow leaving the cartridge; P represents the measured pressure; Pa represents the pressure across the system and F represents the total flow measurement. Once values are determined for the resistors and having pressure drop measurements, the flow balance distribution through and around the cartridge can be determined. - Measurements were made of the cartridge and cartridge/inhaler system dosing configuration and the resistance to airflow through the cartridge, R3 was determined from the formula:
-
- Based on the measurements made as illustrated in
FIGS. 20A-21B , the resistance due to the inlet and outlet ports were determined and the values used to calculate the flow balance of the system in particular the flow balance through the cartridge using the formula above, which is determined as the √P divided by R3. The flow balance distribution through the cartridge for the present inhaler and cartridge system was calculated to be in the range from about 10% to about 30% with an average of approximately 15.92%. - The resistance for the inhaler cartridge system tested herewith can be determined experimentally from the values obtained in the same manner. The resistance for the present inhalers when calculated from the measurements resulted in airflow resistance values of between 0.08 and 0.15 √kPa/liters per minute.
FIG. 22 depicts a linear regression plot illustrating the resistance measured through an exemplary cartridge rig tested or R3, at flow rates between 2 and 9 liters/min. As shown inFIG. 22 , the resistance through the cartridge (R2) tested was determined as equaling to 0.999 √kPa/liters per minute. - Therefore, the inhalers can be structurally configured to have tunable airflow resistance by varying the cross-sectional area at any section of the airflow pathway of the inhaler and cartridge system.
- The preceding disclosures are illustrative embodiments. It should be appreciated by those of skill in the art that the techniques disclosed herein elucidate representative techniques that function well in the practice of the present disclosure. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments that are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.
- Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
- The terms “a,” “an,” “the” and similar referents used in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.
- Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.
- Certain embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations on these described embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventor expects skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
- Furthermore, numerous references have been made to patents and printed publications throughout this specification. Each of the above-cited references and printed publications are individually incorporated herein by reference in their entirety.
- Specific embodiments disclosed herein may be further limited in the claims using consisting of or and consisting essentially of language. When used in the claims, whether as filed or added per amendment, the transition term “consisting of” excludes any element, step, or ingredient not specified in the claims. The transition term “consisting essentially of” limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristic(s). Embodiments of the invention so claimed are inherently or expressly described and enabled herein.
- In closing, it is to be understood that the embodiments of the invention disclosed herein are illustrative of the principles of the present invention. Other modifications that may be employed are within the scope of the invention. Thus, by way of example, but not of limitation, alternative configurations of the present invention may be utilized in accordance with the teachings herein. Accordingly, the present invention is not limited to that precisely as shown and described.
Claims (15)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/863,136 US20160008557A1 (en) | 2008-03-27 | 2015-09-23 | Dry powder inhalation system |
US16/718,732 US20200121869A1 (en) | 2008-03-27 | 2019-12-18 | Dry powder inhalation system |
US18/099,829 US20230149641A1 (en) | 2008-03-27 | 2023-01-20 | Dry powder inhalation system |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4011208P | 2008-03-27 | 2008-03-27 | |
US14337009P | 2009-01-08 | 2009-01-08 | |
US12/413,405 US20090241949A1 (en) | 2008-03-27 | 2009-03-27 | Dry powder inhalation system |
US14/863,136 US20160008557A1 (en) | 2008-03-27 | 2015-09-23 | Dry powder inhalation system |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/413,405 Continuation US20090241949A1 (en) | 2008-03-27 | 2009-03-27 | Dry powder inhalation system |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/718,732 Continuation US20200121869A1 (en) | 2008-03-27 | 2019-12-18 | Dry powder inhalation system |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160008557A1 true US20160008557A1 (en) | 2016-01-14 |
Family
ID=40886853
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/413,405 Abandoned US20090241949A1 (en) | 2008-03-27 | 2009-03-27 | Dry powder inhalation system |
US14/863,136 Abandoned US20160008557A1 (en) | 2008-03-27 | 2015-09-23 | Dry powder inhalation system |
US16/718,732 Abandoned US20200121869A1 (en) | 2008-03-27 | 2019-12-18 | Dry powder inhalation system |
US18/099,829 Pending US20230149641A1 (en) | 2008-03-27 | 2023-01-20 | Dry powder inhalation system |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/413,405 Abandoned US20090241949A1 (en) | 2008-03-27 | 2009-03-27 | Dry powder inhalation system |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/718,732 Abandoned US20200121869A1 (en) | 2008-03-27 | 2019-12-18 | Dry powder inhalation system |
US18/099,829 Pending US20230149641A1 (en) | 2008-03-27 | 2023-01-20 | Dry powder inhalation system |
Country Status (18)
Country | Link |
---|---|
US (4) | US20090241949A1 (en) |
EP (1) | EP2254629B1 (en) |
JP (2) | JP5667041B2 (en) |
KR (1) | KR101541209B1 (en) |
CN (2) | CN101980743B (en) |
AU (1) | AU2009228074B2 (en) |
BR (1) | BRPI0910875B8 (en) |
CA (1) | CA2719205C (en) |
DK (1) | DK2254629T3 (en) |
ES (1) | ES2560875T3 (en) |
HK (1) | HK1151253A1 (en) |
IL (2) | IL208276A0 (en) |
MX (1) | MX371521B (en) |
PL (1) | PL2254629T3 (en) |
PT (1) | PT2254629E (en) |
RU (1) | RU2491103C2 (en) |
SG (2) | SG10201610381XA (en) |
WO (1) | WO2009121020A1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9662461B2 (en) | 2008-06-13 | 2017-05-30 | Mannkind Corporation | Dry powder drug delivery system and methods |
US9700690B2 (en) | 2002-03-20 | 2017-07-11 | Mannkind Corporation | Inhalation apparatus |
US9796688B2 (en) | 2004-08-20 | 2017-10-24 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
US9802012B2 (en) | 2012-07-12 | 2017-10-31 | Mannkind Corporation | Dry powder drug delivery system and methods |
US9854838B1 (en) * | 2015-09-10 | 2018-01-02 | Rodney Laible | Modular mouthpiece assembly for an electronic cigarette |
US10130709B2 (en) | 2011-06-17 | 2018-11-20 | Mannkind Corporation | High capacity diketopiperazine microparticles and methods |
US10130685B2 (en) | 2004-08-23 | 2018-11-20 | Mannkind Corporation | Diketopiperazine salts for drug delivery and related methods |
US10143655B2 (en) | 2005-09-14 | 2018-12-04 | Mannkind Corporation | Method of drug formulation |
US10172850B2 (en) | 2008-12-29 | 2019-01-08 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US10201672B2 (en) | 2008-06-13 | 2019-02-12 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US10258664B2 (en) | 2011-10-24 | 2019-04-16 | Mannkind Corporation | Methods and compositions for treating pain |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10342938B2 (en) | 2008-06-13 | 2019-07-09 | Mannkind Corporation | Dry powder drug delivery system |
US10625034B2 (en) | 2011-04-01 | 2020-04-21 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
US10675421B2 (en) | 2008-06-20 | 2020-06-09 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
US11229757B2 (en) | 2015-04-15 | 2022-01-25 | Philip Morris Products S.A. | Dry powder inhalers with partial dosage delivery |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
US7464706B2 (en) | 1999-07-23 | 2008-12-16 | Mannkind Corporation | Unit dose cartridge and dry powder inhaler |
US7305986B1 (en) | 1999-07-23 | 2007-12-11 | Mannkind Corporation | Unit dose capsules for use in a dry powder inhaler |
MX360812B (en) | 2006-02-22 | 2018-11-16 | Mannkind Corp | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent. |
US9179691B2 (en) | 2007-12-14 | 2015-11-10 | Aerodesigns, Inc. | Delivering aerosolizable food products |
US8539951B1 (en) | 2008-05-27 | 2013-09-24 | Trudell Medical International | Oscillating positive respiratory pressure device |
TWI532497B (en) | 2008-08-11 | 2016-05-11 | 曼凱公司 | Use of ultrarapid acting insulin |
US8327849B2 (en) | 2008-10-28 | 2012-12-11 | Trudell Medical International | Oscillating positive expiratory pressure device |
US8485179B1 (en) | 2009-02-23 | 2013-07-16 | Trudell Medical International | Oscillating positive expiratory pressure device |
US9149589B2 (en) | 2009-02-23 | 2015-10-06 | Trudell Medical International | Method and device for performing orientation dependent oscillating positive expiratory pressure therapy |
US8538707B2 (en) | 2009-03-11 | 2013-09-17 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
KR101875969B1 (en) | 2009-06-12 | 2018-07-06 | 맨카인드 코포레이션 | Diketopiperazine microparticles with defined specific surface areas |
CA2778698A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
CA3114582A1 (en) | 2010-12-22 | 2012-06-28 | Syqe Medical Ltd. | Method and system for drug delivery |
ES2776003T3 (en) * | 2011-05-27 | 2020-07-28 | Boehringer Ingelheim Int | Inhaler and capsule for an inhaler |
CA3207704A1 (en) | 2011-06-06 | 2012-12-13 | Trudell Medical International | Oscillating positive expiratory pressure device |
US9750901B2 (en) * | 2011-06-13 | 2017-09-05 | Shanghai Xiuxin Chenpon Pharmaceutical Technology Co., Ltd. | Dry powder drug-dosing device |
BR112014004921B1 (en) | 2011-09-07 | 2020-12-08 | Concentrx Pharmaceuticals, Inc. | dry powder inhalation device |
CA2858997C (en) * | 2011-12-16 | 2020-03-31 | Indosys Limited | Medicament unit dose cartridge and delivery device |
PT2617451T (en) | 2012-01-17 | 2019-06-14 | Liconsa Laboratorios Sa | Drug delivery assembly, and single dose inhaler for dry powder drug delivery having such assembly |
US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
US9517315B2 (en) | 2012-11-30 | 2016-12-13 | Trudell Medical International | Oscillating positive expiratory pressure device |
BR112015023168B1 (en) | 2013-03-15 | 2021-08-10 | Mannkind Corporation | COMPOSITION OF 3,6-BIS(N-FUMARYL-4-AMINOBUTYL)-2,5-CRYSTALLINE DICETOPIPERAZINE, METHOD OF PRODUCTION OF 3,6-BIS(N-FUMARYL-4-AMINOBUTYL)-2,5-DICETOPIPERAZINE PARTICLES AND USE OF A CRYSTALLINE DICETOPIPERAZINE COMPOSITION |
EP3466396B1 (en) | 2013-07-12 | 2020-09-09 | Trudell Medical International | Huff cough simulation device |
CN114848614A (en) | 2013-07-18 | 2022-08-05 | 曼金德公司 | Heat stable dry powder pharmaceutical compositions and methods |
EP3030294B1 (en) | 2013-08-05 | 2020-10-07 | MannKind Corporation | Insufflation apparatus |
US9849257B2 (en) | 2013-08-22 | 2017-12-26 | Trudell Medical International | Oscillating positive respiratory pressure device |
CN105934391B (en) * | 2014-01-24 | 2018-12-25 | 株式会社细川洋行 | The joint method of Angle supporting bag, the manufacturing method of Angle supporting bag and laminated body |
US10363383B2 (en) | 2014-02-07 | 2019-07-30 | Trudell Medical International | Pressure indicator for an oscillating positive expiratory pressure device |
KR20230117250A (en) | 2014-06-30 | 2023-08-07 | 사이키 메디컬 엘티디. | Drug dose cartridge for an inhaler device |
IL273507B1 (en) | 2014-06-30 | 2024-02-01 | Syqe Medical Ltd | Methods, devices and systems for pulmonary delivery of active agents |
US11298477B2 (en) | 2014-06-30 | 2022-04-12 | Syqe Medical Ltd. | Methods, devices and systems for pulmonary delivery of active agents |
EP3160565B1 (en) | 2014-06-30 | 2021-08-18 | Syqe Medical Ltd. | Devices and systems for pulmonary delivery of active agents |
CA2953082C (en) | 2014-06-30 | 2023-07-11 | Syqe Medical Ltd. | Flow regulating inhaler device |
AU2015283589B2 (en) | 2014-06-30 | 2019-09-12 | Syqe Medical Ltd. | Method and device for vaporization and inhalation of isolated substances |
CN104223363B (en) * | 2014-08-20 | 2017-02-15 | 深圳麦克韦尔股份有限公司 | Inhalator |
CN104223362B (en) * | 2014-08-20 | 2017-02-01 | 深圳麦克韦尔股份有限公司 | Inhalator |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
KR20170102261A (en) * | 2015-01-08 | 2017-09-08 | 컨벡시티 사이언티픽 엘엘씨 | Nebulizer device and reservoir |
DE102015000351B3 (en) * | 2015-01-19 | 2016-05-04 | Klaus Dieter Beller | Powder inhaler, its units powder container and air duct housing, and use of the Pulverinhaltor |
CN104644435B (en) * | 2015-03-05 | 2018-02-02 | 四川海思科制药有限公司 | Powder spray medicine box |
US10004872B1 (en) | 2015-03-06 | 2018-06-26 | D R Burton Healthcare, Llc | Positive expiratory pressure device having an oscillating valve |
WO2016159013A1 (en) | 2015-04-02 | 2016-10-06 | 日本たばこ産業株式会社 | Flavor inhaler |
US10449324B2 (en) | 2015-07-30 | 2019-10-22 | Trudell Medical International | Combined respiratory muscle training and oscillating positive expiratory pressure device |
RU2610779C1 (en) * | 2015-09-28 | 2017-02-15 | Евгений Константинович Агантаев | Single dose dry powder inhaler |
US10857317B2 (en) | 2015-12-04 | 2020-12-08 | Trudell Medical International | Huff cough simulation device |
CA3009599A1 (en) | 2016-01-06 | 2017-07-13 | Syqe Medical Ltd. | Low dose therapeutic treatment |
USD824016S1 (en) * | 2016-01-29 | 2018-07-24 | Mannkind Corporation | Inhaler |
USD824015S1 (en) * | 2016-01-29 | 2018-07-24 | Mannkind Corporation | Inhaler |
USD824510S1 (en) * | 2016-01-29 | 2018-07-31 | Mannkind Corporation | Inhaler |
USD841798S1 (en) * | 2016-01-29 | 2019-02-26 | Mannkind Corporation | Inhaler |
US10506829B2 (en) * | 2016-02-26 | 2019-12-17 | Freelander Innovations USA, LLC | System and method for a vaporizer |
US10238821B2 (en) * | 2016-10-11 | 2019-03-26 | Microdose Therapeutx, Inc. | Inhaler and methods of use thereof |
WO2018097758A1 (en) * | 2016-11-25 | 2018-05-31 | Айна Владимировна ИСАКОВА | Multi-cartridge multi-dose inhalator |
RU168963U1 (en) * | 2016-11-25 | 2017-02-28 | Максим Александрович Котс | MULTI-CARTRIDGE MULTI-DOSE INHALATOR |
EP3600504B1 (en) | 2017-03-28 | 2023-07-12 | Concentrx Pharmaceuticals, Inc. | Device for delivering dry powder medicaments |
US11559723B2 (en) | 2017-05-03 | 2023-01-24 | Trudell Medical International | Combined oscillating positive expiratory pressure therapy and Huff Cough simulation device |
USD834178S1 (en) * | 2017-05-19 | 2018-11-20 | Mannkind Corporation | Inhaler |
EP3630244A1 (en) * | 2017-05-26 | 2020-04-08 | MicroDose Therapeutx, Inc. | Inhaler with synthetic jetting |
KR101992171B1 (en) * | 2017-06-27 | 2019-06-25 | 한국유나이티드제약 주식회사 | Inhaler for dry powder |
GB201713899D0 (en) * | 2017-08-30 | 2017-10-11 | Indosys Ltd | Multi-dose medicament delivery device |
US10953278B2 (en) | 2018-02-02 | 2021-03-23 | Trudell Medical International | Oscillating positive expiratory pressure device |
WO2020031119A1 (en) | 2018-08-07 | 2020-02-13 | Norton (Waterford) Limited | Application of raman spectroscopy for the manufacture of inhalation powders |
CN109011055A (en) * | 2018-09-04 | 2018-12-18 | 佛山市禅城区热拉空间生物科技有限公司 | A kind of capsule drug delivery device |
US20220126034A1 (en) * | 2019-01-14 | 2022-04-28 | Philip Morris Products S.A. | Dry powder inhaler device |
WO2020204991A1 (en) * | 2019-03-29 | 2020-10-08 | Eli Lilly And Company | Medication delivery systems and methods |
USD898187S1 (en) * | 2019-05-21 | 2020-10-06 | Receptor Holdings, Inc. | Inhaler device |
US20210016023A1 (en) * | 2019-07-19 | 2021-01-21 | Convexity Scientific Inc. | Mouthpiece with an enhanced spraying effect, and portable nebulizer thereof |
US11528939B2 (en) | 2019-11-26 | 2022-12-20 | Altria Client Services Llc | Non-nicotine pod assemblies and non-nicotine e-vaping devices |
US11564416B2 (en) | 2019-11-26 | 2023-01-31 | Altria Client Services Llc | Non-nicotine pod assemblies and non-nicotine e-vaping devices |
US11490656B2 (en) | 2019-11-26 | 2022-11-08 | Altria Client Services Llc | Nicotine pod assemblies and nicotine e-vaping devices |
US11576432B2 (en) | 2019-11-26 | 2023-02-14 | Altria Client Services Llc | Nicotine pod assemblies and nicotine e-vaping devices |
US11528937B2 (en) | 2019-11-26 | 2022-12-20 | Altria Client Services Llc | Nicotine pod assemblies and nicotine e-vaping devices |
US11596172B2 (en) | 2019-11-26 | 2023-03-07 | Altria Client Services Llc | Non-nicotine pod assemblies and non-nicotine e-vaping devices |
US11484062B2 (en) | 2019-11-26 | 2022-11-01 | Altria Client Services Llc | Nicotine pod assemblies and nicotine e-vaping devices |
US11528938B2 (en) | 2019-11-26 | 2022-12-20 | Altria Client Services Llc | Non-nicotine pod assemblies and non-nicotine e-vaping devices |
FR3138875A1 (en) | 2022-08-18 | 2024-02-23 | Aptar France Sas | Dry powder inhaler |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5715811A (en) * | 1994-05-26 | 1998-02-10 | Unisia Jecs Corporation | Inhaling type medicine administering device and using method therefor |
US5755218A (en) * | 1991-03-05 | 1998-05-26 | Aradigm Corporation | Method and apparatus for releasing a controlled amount of aerosol medication over a selectable time interval |
US20040182387A1 (en) * | 1999-07-23 | 2004-09-23 | Mannkind Corporation | Unit dose cartridge and dry powder inhaler |
US20050018898A1 (en) * | 2003-07-24 | 2005-01-27 | White Jerry L. | Method and apparatus for performing failure analysis with fluorescence inks |
US20050252508A1 (en) * | 2004-02-05 | 2005-11-17 | Joachim Koerner | Dosing device |
US20060239934A1 (en) * | 2005-03-31 | 2006-10-26 | Mannkind Corporation | Superior control of blood glucose in diabetes treatment |
US20070017511A1 (en) * | 2003-05-28 | 2007-01-25 | Hitachi, Ltd. | Inhalation type dosing device |
WO2007068896A1 (en) * | 2005-12-12 | 2007-06-21 | Glaxo Group Limited | Manifold for use in medicament dispenser |
EP1923087A2 (en) * | 1999-07-23 | 2008-05-21 | MannKind Corporation | Unit dose capsules and dry powder inhaler |
US20100108062A1 (en) * | 2006-03-10 | 2010-05-06 | Dose One, Llc | Medication inhaler |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2549303A (en) * | 1949-04-20 | 1951-04-17 | Bristol Lab Inc | Inhaler for crystalline pencilllin or the like |
US3337740A (en) * | 1962-02-13 | 1967-08-22 | Deering Milliken Res Corp | Process for separating acrylic acid from impurities |
US3669113A (en) * | 1966-03-07 | 1972-06-13 | Fisons Ltd | Inhalation device |
US3518340A (en) * | 1968-04-15 | 1970-06-30 | Dow Corning | Method of forming silicone rubber drug carriers |
US3622053A (en) * | 1969-12-10 | 1971-11-23 | Schering Corp | Aerosol inhaler with flip-up nozzle |
BE794951A (en) * | 1972-02-03 | 1973-05-29 | Parke Davis & Co | WATER SOLUBLE PACKAGING |
US3823843A (en) * | 1972-10-26 | 1974-07-16 | Lilly Co Eli | Locking capsule |
US3856142A (en) * | 1973-01-24 | 1974-12-24 | Mine Safety Appliances Co | Inhalant package |
FR2224175B1 (en) * | 1973-04-04 | 1978-04-14 | Isf Spa | |
GB1479283A (en) * | 1973-07-23 | 1977-07-13 | Bespak Industries Ltd | Inhaler for powdered medicament |
DE2502251A1 (en) * | 1975-01-17 | 1976-07-22 | Schering Ag | DEVICE FOR INHALATION OF POWDERED SOLIDS |
US4040536A (en) * | 1975-05-05 | 1977-08-09 | R. P. Scherer Corporation | Locking hard gelatin capsule |
GB1598081A (en) * | 1977-02-10 | 1981-09-16 | Allen & Hanburys Ltd | Inhaler device for dispensing medicaments |
IE46865B1 (en) * | 1977-04-29 | 1983-10-19 | Allen & Hanburys Ltd | Device for dispensing medicaments |
US4148308A (en) * | 1977-05-31 | 1979-04-10 | Sayer William J | Mouthpiece with a tongue retractor |
US4268460A (en) * | 1977-12-12 | 1981-05-19 | Warner-Lambert Company | Nebulizer |
CA1113044A (en) * | 1977-12-16 | 1981-11-24 | J. Paul Leblond | Personal repellant device |
DE2849493C2 (en) * | 1978-11-15 | 1982-01-14 | Carl Heyer Gmbh, Inhalationstechnik, 5427 Bad Ems | Hand-held aerosol dispenser |
US4407525A (en) * | 1979-10-04 | 1983-10-04 | Gao Gesellschaft Fur Automation Und Organisation Mbh | Identification card with hallmark for authentication by incident and transmitted light |
DE3167658D1 (en) * | 1980-12-12 | 1985-01-17 | Combi Co | Inhaler |
ATE23272T1 (en) * | 1981-07-08 | 1986-11-15 | Draco Ab | POWDER INHALER. |
SE438261B (en) * | 1981-07-08 | 1985-04-15 | Draco Ab | USE IN A DOSHALATOR OF A PERFORED MEMBRANE |
US4487327A (en) * | 1982-12-21 | 1984-12-11 | Grayson Robert E | Locking capsule |
US4592348A (en) * | 1984-12-17 | 1986-06-03 | Waters Iv William C | Aerosol inhaler |
AT384552B (en) * | 1985-08-01 | 1987-12-10 | Hurka Wilhelm | INHALATION DEVICE FOR DOSING AND DISTRIBUTING SOLID BODIES INTO THE BREATHING AIR |
SE453566B (en) * | 1986-03-07 | 1988-02-15 | Draco Ab | POWDER INHALATOR DEVICE |
US4926852B1 (en) * | 1986-06-23 | 1995-05-23 | Univ Johns Hopkins | Medication delivery system phase one |
KR890003520Y1 (en) * | 1986-12-20 | 1989-05-27 | 주식회사 서흥캅셀 | Medicinal capsule |
ATE104867T1 (en) * | 1988-10-04 | 1994-05-15 | Univ Johns Hopkins | INHALATION DEVICE FOR AEROSOLS. |
IT1228460B (en) * | 1989-02-23 | 1991-06-19 | Phidea S R L | DISPOSABLE INHALER WITH PRE-PERFORATED CAPSULE |
US4991605A (en) * | 1989-04-24 | 1991-02-12 | Philip Morris Incorporated | Container for additive materials for smoking articles |
US5067500A (en) * | 1989-04-24 | 1991-11-26 | Philip Morris Incorporated | Container for additive materials for smoking articles |
EP0705614B1 (en) * | 1989-04-28 | 2002-09-25 | Riker Laboratories, Inc. | Dry powder inhalation device |
DK544589D0 (en) * | 1989-11-01 | 1989-11-01 | Novo Nordisk As | MANUALLY OPERATED DEVICE FOR DISPENSING A PRESCRIBED QUANTITY OF A POWDER-SHAPED SUBSTANCE |
US5328464A (en) * | 1990-04-24 | 1994-07-12 | Science Incorporated | Closed drug delivery system |
US5170801A (en) * | 1990-10-02 | 1992-12-15 | Glaxo Inc. | Medical capsule device actuated by radio-frequency (rf) signal |
FR2667509B1 (en) * | 1990-10-04 | 1995-08-25 | Valois | POWDER INHALER, DEVICE FOR PACKAGING POWDER MICRODOSES IN THE FORM OF BANDS SUITABLE FOR USE IN A POWDER INHALER, AND METHOD FOR MANUFACTURING SUCH BANDS. |
GB9027234D0 (en) * | 1990-12-15 | 1991-02-06 | Harris Pharma Ltd | An inhalation device |
DE69127826T2 (en) * | 1990-12-17 | 1998-04-09 | Minnesota Mining & Mfg | INHALATION DEVICE |
US5404871A (en) * | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
US5797391A (en) * | 1991-03-28 | 1998-08-25 | Rhone-Poulenc Rorer Limited | Inhaler |
US5243970A (en) * | 1991-04-15 | 1993-09-14 | Schering Corporation | Dosing device for administering metered amounts of powdered medicaments to patients |
US5492112A (en) * | 1991-05-20 | 1996-02-20 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
US6055980A (en) * | 1991-05-20 | 2000-05-02 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
US5327883A (en) * | 1991-05-20 | 1994-07-12 | Dura Pharmaceuticals, Inc. | Apparatus for aerosolizing powdered medicine and process and using |
FR2676929B1 (en) * | 1991-05-30 | 1994-02-11 | Aerosols Bouchage Ste Fse | POWDER INHALER. |
JP3230056B2 (en) * | 1991-07-02 | 2001-11-19 | インヘイル・インコーポレーテッド | Device for forming an aerosolized dose of a drug |
US5337740A (en) * | 1991-08-01 | 1994-08-16 | New England Pharmaceuticals, Inc. | Inhalation devices |
DE4211475A1 (en) * | 1991-12-14 | 1993-06-17 | Asta Medica Ag | POWDER INHALATOR |
US5476093A (en) * | 1992-02-14 | 1995-12-19 | Huhtamaki Oy | Device for more effective pulverization of a powdered inhalation medicament |
US5785049A (en) * | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
GB2270293A (en) * | 1992-09-05 | 1994-03-09 | Medix Ltd | Drug dispensing system |
CZ282964B6 (en) * | 1992-10-19 | 1997-11-12 | Dura Pharmaceuticals, Inc. | Apparatus for making aerosol from a pulverized medicament |
EP0674533B1 (en) * | 1992-12-18 | 1999-03-10 | Schering Corporation | Inhaler for powdered medications |
US5896855A (en) * | 1992-12-24 | 1999-04-27 | Rhone-Poulenc Rorer Limited | Multi dose inhaler apparatus |
FR2700279B1 (en) * | 1993-01-14 | 1995-03-17 | Valois | Portable device for projecting doses of a fluid substance using a stream of compressed air. |
US5888477A (en) * | 1993-01-29 | 1999-03-30 | Aradigm Corporation | Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin |
US5727546A (en) * | 1993-08-18 | 1998-03-17 | Fisons Plc | Powder inhaler with breath flow regulation valve |
US5524613A (en) * | 1993-08-25 | 1996-06-11 | Habley Medical Technology Corporation | Controlled multi-pharmaceutical inhaler |
US5505194A (en) * | 1994-03-23 | 1996-04-09 | Abbott Laboratories | Aerosol inhalation device having slideably and rotatably connected elliptical cylinder portions |
US5483954A (en) * | 1994-06-10 | 1996-01-16 | Mecikalski; Mark B. | Inhaler and medicated package |
SE9404439D0 (en) * | 1994-12-21 | 1994-12-21 | Astra Ab | Inhalation device |
US5901703A (en) * | 1995-02-06 | 1999-05-11 | Unisia Jecs Corporation | Medicine administering device for nasal cavities |
US5645051A (en) * | 1995-04-21 | 1997-07-08 | Dura Pharmaceuticals, Inc. | Unit dose dry powder inhaler |
US5921237A (en) * | 1995-04-24 | 1999-07-13 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
US5622166A (en) * | 1995-04-24 | 1997-04-22 | Dura Pharmaceuticals, Inc. | Dry powder inhaler delivery system |
US5714007A (en) * | 1995-06-06 | 1998-02-03 | David Sarnoff Research Center, Inc. | Apparatus for electrostatically depositing a medicament powder upon predefined regions of a substrate |
SE504458C2 (en) * | 1995-06-21 | 1997-02-17 | Lars Gunnar Nilsson | Inhalator for electrical dosing of substances |
DE19523516C1 (en) * | 1995-06-30 | 1996-10-31 | Asta Medica Ag | Inhaler for administering medication from blister packs |
US5758638A (en) * | 1995-07-24 | 1998-06-02 | Kreamer; Jeffry W. | Indicator for a medicament inhaler |
US5746197A (en) * | 1995-08-18 | 1998-05-05 | Williams; Jeffery W. | Extension for metered dose inhaler |
KR0124764Y1 (en) * | 1995-09-23 | 1998-09-15 | 양주환 | Medical capsule |
US6470884B2 (en) * | 1996-01-29 | 2002-10-29 | Aventis Pharma Limited | Capsule opening arrangement for use in a powder inhaler |
US5699789A (en) * | 1996-03-11 | 1997-12-23 | Hendricks; Mark R. | Dry powder inhaler |
JP3328132B2 (en) * | 1996-03-21 | 2002-09-24 | 株式会社ユニシアジェックス | Inhaler type dispenser |
CZ343798A3 (en) * | 1996-04-29 | 1999-02-17 | Dura Pharmaceuticals, Inc. | Inhaling system for inhaling dry powder |
GB9626263D0 (en) * | 1996-12-18 | 1997-02-05 | Innovata Biomed Ltd | Powder inhaler |
GB9626233D0 (en) * | 1996-12-18 | 1997-02-05 | Chawla Brinda P S | Medicament packaging and deliveery device |
DE69829139T2 (en) * | 1997-01-30 | 2006-04-06 | Hitachi, Ltd. | MEDICATOR OF INTAKE TYPE |
US6006747A (en) * | 1997-03-20 | 1999-12-28 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
US5904139A (en) * | 1997-03-28 | 1999-05-18 | Hauser; Stephen G. | Breath coordinated inhaler |
CA2212430A1 (en) * | 1997-08-07 | 1999-02-07 | George Volgyesi | Inhalation device |
US6394085B1 (en) * | 1997-09-25 | 2002-05-28 | Norton Healthcare Ltd. | Inhaler spacer |
US6073629A (en) * | 1997-09-25 | 2000-06-13 | Norton Healthcare Ltd. | Inhaler spacer |
US6116238A (en) * | 1997-12-02 | 2000-09-12 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
JP3530004B2 (en) * | 1998-02-06 | 2004-05-24 | 株式会社日立ユニシアオートモティブ | Inhalation type dispenser |
US6158431A (en) * | 1998-02-13 | 2000-12-12 | Tsi Incorporated | Portable systems and methods for delivery of therapeutic material to the pulmonary system |
UA73924C2 (en) * | 1998-10-09 | 2005-10-17 | Nektar Therapeutics | Device for delivering active agent formulation to lungs of human patient |
US6644315B2 (en) * | 1999-06-18 | 2003-11-11 | Saeed Ziaee | Nasal mask |
US6427688B1 (en) * | 2000-02-01 | 2002-08-06 | Dura Pharmaceuticals, Icn. | Dry powder inhaler |
US6363932B1 (en) * | 2000-07-06 | 2002-04-02 | Clinical Technologies, Inc. | Aerosol enhancement device |
US6681768B2 (en) * | 2001-06-22 | 2004-01-27 | Sofotec Gmbh & Co. Kg | Powder formulation disintegrating system and method for dry powder inhalers |
US7219664B2 (en) * | 2005-04-28 | 2007-05-22 | Kos Life Sciences, Inc. | Breath actuated inhaler |
EP2077882A2 (en) * | 2006-10-25 | 2009-07-15 | Nektar Therapeutics | Powder dispersion apparatus, method of making and using the apparatus, and components that can be used on the apparatus and other devices |
-
2009
- 2009-03-27 MX MX2010010513A patent/MX371521B/en active IP Right Grant
- 2009-03-27 PT PT97245393T patent/PT2254629E/en unknown
- 2009-03-27 JP JP2011502116A patent/JP5667041B2/en active Active
- 2009-03-27 EP EP09724539.3A patent/EP2254629B1/en active Active
- 2009-03-27 CN CN200980110968.7A patent/CN101980743B/en active Active
- 2009-03-27 US US12/413,405 patent/US20090241949A1/en not_active Abandoned
- 2009-03-27 SG SG10201610381XA patent/SG10201610381XA/en unknown
- 2009-03-27 WO PCT/US2009/038668 patent/WO2009121020A1/en active Application Filing
- 2009-03-27 CA CA2719205A patent/CA2719205C/en active Active
- 2009-03-27 PL PL09724539T patent/PL2254629T3/en unknown
- 2009-03-27 BR BRPI0910875A patent/BRPI0910875B8/en active IP Right Grant
- 2009-03-27 DK DK09724539.3T patent/DK2254629T3/en active
- 2009-03-27 CN CN201410075084.5A patent/CN103908712A/en active Pending
- 2009-03-27 RU RU2010143890/14A patent/RU2491103C2/en active
- 2009-03-27 AU AU2009228074A patent/AU2009228074B2/en active Active
- 2009-03-27 KR KR1020107024007A patent/KR101541209B1/en active IP Right Grant
- 2009-03-27 SG SG2013050125A patent/SG192447A1/en unknown
- 2009-03-27 ES ES09724539.3T patent/ES2560875T3/en active Active
-
2010
- 2010-09-20 IL IL208276A patent/IL208276A0/en active IP Right Grant
-
2011
- 2011-05-27 HK HK11105308.3A patent/HK1151253A1/en unknown
-
2014
- 2014-09-18 IL IL234748A patent/IL234748A/en active IP Right Grant
- 2014-10-07 JP JP2014206394A patent/JP2015027559A/en active Pending
-
2015
- 2015-09-23 US US14/863,136 patent/US20160008557A1/en not_active Abandoned
-
2019
- 2019-12-18 US US16/718,732 patent/US20200121869A1/en not_active Abandoned
-
2023
- 2023-01-20 US US18/099,829 patent/US20230149641A1/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5755218A (en) * | 1991-03-05 | 1998-05-26 | Aradigm Corporation | Method and apparatus for releasing a controlled amount of aerosol medication over a selectable time interval |
US5715811A (en) * | 1994-05-26 | 1998-02-10 | Unisia Jecs Corporation | Inhaling type medicine administering device and using method therefor |
US20040182387A1 (en) * | 1999-07-23 | 2004-09-23 | Mannkind Corporation | Unit dose cartridge and dry powder inhaler |
EP1923087A2 (en) * | 1999-07-23 | 2008-05-21 | MannKind Corporation | Unit dose capsules and dry powder inhaler |
US20070017511A1 (en) * | 2003-05-28 | 2007-01-25 | Hitachi, Ltd. | Inhalation type dosing device |
US20050018898A1 (en) * | 2003-07-24 | 2005-01-27 | White Jerry L. | Method and apparatus for performing failure analysis with fluorescence inks |
US20050252508A1 (en) * | 2004-02-05 | 2005-11-17 | Joachim Koerner | Dosing device |
US20060239934A1 (en) * | 2005-03-31 | 2006-10-26 | Mannkind Corporation | Superior control of blood glucose in diabetes treatment |
WO2007068896A1 (en) * | 2005-12-12 | 2007-06-21 | Glaxo Group Limited | Manifold for use in medicament dispenser |
US20100108062A1 (en) * | 2006-03-10 | 2010-05-06 | Dose One, Llc | Medication inhaler |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9700690B2 (en) | 2002-03-20 | 2017-07-11 | Mannkind Corporation | Inhalation apparatus |
US9796688B2 (en) | 2004-08-20 | 2017-10-24 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
US10130685B2 (en) | 2004-08-23 | 2018-11-20 | Mannkind Corporation | Diketopiperazine salts for drug delivery and related methods |
US10143655B2 (en) | 2005-09-14 | 2018-12-04 | Mannkind Corporation | Method of drug formulation |
US10201672B2 (en) | 2008-06-13 | 2019-02-12 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US10751488B2 (en) | 2008-06-13 | 2020-08-25 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US10342938B2 (en) | 2008-06-13 | 2019-07-09 | Mannkind Corporation | Dry powder drug delivery system |
US9662461B2 (en) | 2008-06-13 | 2017-05-30 | Mannkind Corporation | Dry powder drug delivery system and methods |
US10675421B2 (en) | 2008-06-20 | 2020-06-09 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
US10172850B2 (en) | 2008-12-29 | 2019-01-08 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US10625034B2 (en) | 2011-04-01 | 2020-04-21 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
US10130709B2 (en) | 2011-06-17 | 2018-11-20 | Mannkind Corporation | High capacity diketopiperazine microparticles and methods |
US10258664B2 (en) | 2011-10-24 | 2019-04-16 | Mannkind Corporation | Methods and compositions for treating pain |
US9802012B2 (en) | 2012-07-12 | 2017-10-31 | Mannkind Corporation | Dry powder drug delivery system and methods |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
US11229757B2 (en) | 2015-04-15 | 2022-01-25 | Philip Morris Products S.A. | Dry powder inhalers with partial dosage delivery |
US9854838B1 (en) * | 2015-09-10 | 2018-01-02 | Rodney Laible | Modular mouthpiece assembly for an electronic cigarette |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230149641A1 (en) | Dry powder inhalation system | |
US11241549B2 (en) | Dry powder inhaler and system for drug delivery | |
US9662461B2 (en) | Dry powder drug delivery system and methods | |
RU2487731C2 (en) | Advanced dry powder delivery system | |
US9393372B2 (en) | Dry powder drug delivery system | |
AU2015201158B2 (en) | A dry powder inhalation system | |
AU2018226461A1 (en) | A dry powder inhaler and system for drug delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MANNKIND CORPORATION, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SMUTNEY, CHAD C.;KINSEY, P. SPENCER;POLIDORO, JOHN M.;AND OTHERS;SIGNING DATES FROM 20090409 TO 20090604;REEL/FRAME:036861/0106 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
AS | Assignment |
Owner name: MANNKIND CORPORATION, CALIFORNIA Free format text: RELEASE BY SECURED PARTY;ASSIGNORS:DEERFIELD PRIVATE DESIGN FUND II, L.P.;DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.;HORIZON SANTE FLML SARL;REEL/FRAME:050044/0138 Effective date: 20190806 Owner name: MIDCAP FINANCIAL TRUST, AS AGENT, MARYLAND Free format text: SECURITY INTEREST;ASSIGNORS:MANNKIND CORPORATION;MANNKIND LLC;REEL/FRAME:050044/0181 Effective date: 20190806 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |